 
STILL [ADDRESS_914263] number  [STUDY_ID_REMOVED]  
Document Date  06/07/2020  
 
STILL 3  
Targeting Auditory Hallucinations with Alternating 
Current Stimulation  
Protocol Identifying Number: 17-1364 
Principal Investigator:  [INVESTIGATOR_124]. Flavio Frohlich, PhD  
Co-Investigators: [CONTACT_226273], MD, [CONTACT_226274], MD  
Funded by : [CONTACT_676262] (NIMH)  
Draft or Version Number:  v .1.[ADDRESS_914264] Updated: [ADDRESS_914265] OF ABBREVIATIONS  ....................................................................................................................................... 5  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 7  
PROTOCOL SUMMARY  ........................................................................................................................................... 7  
SCHEMATIC OF STUDY DESIGN  .......................................................................................................................... 9  
1 KEY ROLES  .................................................................................................................................................... 9  
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ...................... [ADDRESS_914266] description  ................................................................................................................. 18 
6.1.1 Device Description  ......................................................................................................... 18 
6.1.2  Operation  ......................................................................................................................... 18 
6.1.3  Safety Precautions  ......................................................................................................... 19 
7 STUDY PROCEDURES/EVALUATIONS  ................................................................................................. [ADDRESS_914267] of Care Study Procedures  ............................................................................................... 22 
7.3 Laboratory Procedures/Evaluations  ................................................................................................ 22 
7.3.1  Clinical Laboratory Evaluations  .................................................................................... 22 
7.3.2  Other Assays or Procedures  ........................................................................................ 22 
7.4 Study Schedule  .................................................................................................................................. 23 
7.4.1  Screening  ........................................................................................................................ 23 
7.4.2  Enrollment/Baseline  ....................................................................................................... 23 
7.4.3  Stimulation Week  ........................................................................................................... 24 
7.4.4  Structural MRI Visit  ........................................................................................................ 25 
7.4.5  Maintenance Sessions  .................................................................................................. 26 
7.4.6  Final Study Visit  .............................................................................................................. 27 
7.4.7  Case Study  ...................................................................................................................... 27 
7.4.8  Schedule of Events Table  ............................................................................................. 28 
iii 
 7.5 Participant Access to Study Agent At Study Closure  ................................................................... 28 
8 ASSESSMENT OF SAFETY  ...................................................................................................................... 28 
8.1 Specification of Safety Parameters  ................................................................................................. 28 
8.1.1  Definition of Adverse Events (AE)  ............................................................................... 29 
8.1.2  Definition of Serious Adverse Events (SAE)  .............................................................. 30 
8.1.3  Definition of Unanticipated Problems (UP)  ................................................................. 30 
8.2 Classification of an Adverse Event  ................................................................................................. 31 
8.2.1  Severity of Event  ............................................................................................................ 31 
8.2.2  Relationship to Study Agent  ......................................................................................... 31 
8.3 Time Period and Frequency for Event Assessment and Follow -Up .......................................... 31 
8.4 Reporting Procedures  ....................................................................................................................... 31 
8.4.1  Reporting of Pregnancy  ................................................................................................ 32 
8.5 Study Halting Rules  ........................................................................................................................... 32 
8.6 Safety Oversight  ................................................................................................................................ 32 
9 CLINICAL MONI TORING  ............................................................................................................................ 33 
10 STATISTICAL CONSIDERATIONS  .......................................................................................................... 34 
10.1  STUDY HYPOTHESES  .................................................................................................................... 34 
10.2  STATISTICAL ANALYSIS PLANS  .................................................................................................. 34 
10.3  Sample Size Considerations  ............................................................................................................ 36 
10.4  Randomization And Blinding ............................................................................................................ 41 
10.4.1  Enrollment/ Randomization/ Masking Procedures  .................................................... 41 
10.4.2  Evaluation of Success of Blinding  ............................................................................... 41 
10.4.3  Breaking the Study Blind/Participant Code  ................................................................ 41 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 41 
12 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................... [ADDRESS_914268]  ................................................................................................................ 43 
12.3  Informed Consent Process  ............................................................................................................... 43 
12.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ... [ADDRESS_914269] KEEPI[INVESTIGATOR_1645]  .......................................................................................... 45 
13.1  Data Collection and Management Responsibilities  ...................................................................... 45 
13.2  Data Capture Methods  ...................................................................................................................... 45 
13.3  Types of Data  ..................................................................................................................................... 45 
13.4  Study Records Retention  .................................................................................................................. 46 
13.5  Protocol Deviations ............................................................................................................................ 46 
13.6  Publication and Data Sharing Policy  ............................................................................................... 47 
14 STUDY ADMINISTRATION  ........................................................................................................................ 47 
14.1  Study Leadership  ............................................................................................................................... 47 
15  LITERATU RE REFERENCES .................................................................................................................... 47 
APPENDIX A: AE REPORT FORM ....................................................................................................................... 51 
iv 
 APPENDIX B: AE LOG  ............................................................................................................................................ 53 
APPENDIX C: SAE REPORT FORM  .................................................................................................................... 54 
APPENDIX D: UE/SAE LOG  ................................................................................................................................... 58 
APPENDIX E: INFORMED CONSENT QUIZ  ....................................................................................................... 59 
APPENDIX F: DELEGATION OF AUTHORITY  ................................................................................................... 60 
APPENDIX G: NOTE TO FILE  ............................................................................................................................... 61 
APPENDIX H: PROTOCOL DEVIATION LOG  .................................................................................................... 62 
APPENDIX I: TRAINING LOG  ................................................................................................................................ 63 
APPENDIX J: TELEPHONE RECRUITMENT SCRIPT  ...................................................................................... [ADDRESS_914270] Assertive Community Treatment  
AE Adverse Event  
AHRS  Auditory Hallucination Rating Scale  
ANOVA  Analysis of Variance  
BACS  Brief Assessment of Cognition in Schizophrenia  
BDNF  Brain Derived Neurotrophic Factor  
CAPA  Corrective and Preventative Action  
CFR Code of Federal Regulations  
Co-I Co-Investigator  
CRF Case Report Form  
CRMS  Clinical Research Management System  
dl-PFC Dorso -lateral Prefrontal Cortex  
DMV  Department of Motor Vehicles  
DSM -IV Diagnostic and Statistical Manual of Mental Disorders (Version IV)  
DSMB  Data and Safety Monitoring Board  
eCRF  Electronic Case Report Form  
EEG Electroencephalogram  
ECG Electrocardiogram  
GCP Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountabilit y Act  
HRV  Heart Rate Variability  
HPSVQ  Hamilton Program for Schizophrenia Voices Questionnaire  
Hz Hertz  
ICA Independent Component Analysis  
ICF Informed Consent Form  
IDE Investigational Device Exemption  
IRB Institutional Review Board  
JAMA  Journal of the American Medical Association  
LAR Legally Authorized Representative  
mA Milli -amps  
MRI Magentic Resonance Imaging  
NCPRC  North Carolina Psychiatric Research Center  
NIBs  Non -Invasive Brain Stimulation  
NIH National Institutes of Health  
NRB  Neurosciences Research Building  
OHRE  Office of Human Research Ethics  
OHRP  Office for Human Research Protections  
PANSS  Positive and Negative Syndrome Scale  
PI [INVESTIGATOR_100867]/Serious Adverse Experience  
SCID  Structured Clinical Interview for DSM -IV Axis I Disorders  
sMRI  Structural Magnetic Resonance Imaging  
SOP Standard Operating Procedure  
tACS  Transcranial Alternating Current Stimulation  
tDCS  Transcranial Direct Current Stimulation  
TMS  Transcranial Magnetic Stimulation  
 
6 
 TPJ Temporo -parietal Junction  
UDS  Urine Drug Screen  
UE Unexpected Event  
UNC  University of North Carolina  
UNC -CH University of North Carolina at Chapel Hill  
US [LOCATION_002]  
 
  
 
7 
 STATEMENT OF COMPLIANCE  
The study will be carried out in accordance with Good Clinical Practice (GCP) as required by [CONTACT_716]  
● [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 
50, 21 CFR Part 56, and 21 CFR Part 312)  
● ICH E6; 62 Federal Register [ZIP_CODE] (May 9, 1997)  
All key personnel (all individuals responsible for the design and conduct of this study) have completed Human 
Participants Protection and HIPAA Training.  
PROTOCOL SUMMARY  
 
Title  STILL [ADDRESS_914271] week,  and to a sham or active maintenance regimen.  Equal numbers of participants will be assigned by [CONTACT_676263] -sequence groups : tACS -tACS, tACS -sham, sham -
tACS, sham -sham.  
      Participation will involve 1 to 18 visits. At the initial  phone  session, informed 
consent will be obtained and subjects will be screened for eligibility. Participants will be contact[CONTACT_84658]  2 weeks for a second phone screening session to 
determine stability of auditory hallucination symptoms , utilizing the Auditory 
Hallucinations Rating Scale (AHRS, attachment 3) . If the AHRS scores are with 
+20% of their previous score, they will be considered eligible. If the AHRS scores 
do not fall within this range, participants will be rescheduled for a third or fourth 
screeni ng session separated by [ADDRESS_914272] stable AHRS scores, they will not be eligible to 
participate.  
     Eligible participants will be scheduled for their daily stimulation sessions which 
will include a daily assessment of stimulation side -effects. Clinical assessments  of 
auditory hallucinations  will be administered with the AHRS and the self -
administered Hamilton Program for Schizophrenia Voices (HPSVQ) . These 
measurements will be assessed at  the time of enrollment into the study 
(baseline) , at the first day of stimulation, at the fifth day of stimulation, and once 
weekly for 8 weeks of maintenance stimulation sessions . Neurophysiological (EEG) 
and cognitive assays will be performed day [ADDRESS_914273] a randomized  clinical trial to investigate the 
ability of  tACS to renormalize pathological alpha oscillations in dl- PFC of patients 
with schizophrenia and schizoaffective disorder and experiencing auditory 
hallucinations   by [CONTACT_676264] . We also aim to evaluate 
the ability of an 8 -week maintenance regimen  to prolong the duration of 
stimulation -induced clinical benefits  in tems of longitudinal changes in AHRS 
scores and other measures.   We hypothesize that (1) tAC S reduces auditory 
hallucination symptoms after 5 consecutive days of daily stimulation and (2) 
repeat application of tACS during a follow -up maintenance regimen extends the 
duration of the clinical benefits of the initial stimulation .  
     Our  secondary objective is to collect further data demonstrating the value of 
oscillations  and connectivity measures derived from EEG data as novel biomarkers 
in the treatment of medication refractory auditory hallucinations in schizophrenia 
with transcranial current stimulation. To reach this objective, we will test the 
working hypothesis that (1) baseline impairment in EEG oscillations  and 
connectivity  predicts treatment success, and (2) changes in these markers 
correlate with improvement of clinical symptom presentation as measured by [CONTACT_676265], PANSS ( Attachment 5 ), and BACS (Attachment 6).  We will collect  data to 
support our working hypothesis by [CONTACT_226234] -head EEG data  with 
individual locations of scalp electrodes and structural MRI from all patient s in our 
study (40 patients from Aim 1) before and immediately after the five day course of stimulation and at each maintenance stimulation visits for weeks 1, [ADDRESS_914274] a total of 15 to 1 8 
visits; an initial session, [ADDRESS_914275] no longer than 2 hours. Maintenance  stimulation 
sessions weeks 1 and 3 will take approximately 3 hours. Maintenance sessions weeks 2, 4, 5, 6, and 7 will take approximately 2 hours. Maintenance session week 
8 will take approximately 5 hours.   We estimate that total participation to be 
appr oximately 35-39 hours.  
 
SCHEMATIC OF STUDY DESIGN  
At enrollment,  the 40 eligible enrollees will be allocated by [CONTACT_676266] -sequence groups: 
tACS -tACS, tACS -sham, sham -sham, sham -tACS) (10 participants per sequence). The randomization will be 
stratified by [CONTACT_4321]. 
 
1 KEY ROLES  
Individua ls: Principal Investigator:   [INVESTIGATOR_61560], Ph.D.  
 Co-Investigator: Fred Jarskog M.D., John Gilmore, M.D  
 Flavio Frohlich Ph.D. – Principal Investigator     
[CONTACT_11604] - Chapel Hill Department of Psychiatry  
Email:  [EMAIL_1219]  
Office:  4109 Neuroscience Research Building 
Phone:  (919) 966 -4584  
 Fred Jarskog M.D - Co-Investigator  
UNC - Chapel Hill Department of Psychiatry  
Email:  [EMAIL_4462]  
Office:  Medical School Wing D, Rm 254  
Phone:  (919) 843 -7683  
Phone Screening
 Initial Session
Screening 
Sessions
(1 to 3)
Week of Stimulation
(5 consecutive days)
Maintenance 
Stimulation
(Weeks 1 to 7) 
Maintenance 
Stimulation
(Week 8)
 
10 
  
John Gilmore M.D - Co-Investigator  
UNC - Chapel Hill Department of Psychiatry  
Email:  [EMAIL_12923] 
Office:  304 MacNider Hall  
Phone:  (919) 445 -0209  
 
Rachel Force, Ph.D. – Clinical Trials Director  
UNC- Chapel Hill Department of Psychiatry  
Email: [EMAIL_12924]  
Office: Medical School Wing C -233 
Phone: (919)966- 9929  
 
Institutions:  University of North Carolina - Chapel Hill  
 
Other:  IRB 
University of North Carolina -Chapel Hill 
[ADDRESS_914276]  
Bldg#385, Second Floor  
CB #7097  
Chapel Hill, NC [ZIP_CODE]- 7097  
(919) 966- 3113  
National Institute of Mental Health  
Sponsored Programs Office, SOM  
1140- C Bioinformatics Bldg., CB9525  
Chapel  Hill, NC [ZIP_CODE]- 9525  
 
 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
2.1 BACKGROUND INFORMATION  
About, 30% of patients with schizophrenia have auditory hallucinations that are refractory to antipsychotic 
medication and cause a significant decrease in quality of life (Shergill, Murray et al. 1998). All effective antipsychotics introduced over the past [ADDRESS_914277] been limited to the use of tDCS (Brunelin, Mondino et al. 2012). However, tDCS does not specifically target the known deficits in neuronal synchronization (alpha frequency band functional connection ) 
between the cortical areas that may play a causal role in auditory hallucinations (Winterer, Coppola et al.  2003).  
Patients with schizophrenia exhibit disorganized neuronal network dynamics such as hypoactivity in the dorso -
lateral prefrontal cortex (dl -PFC) and hyperactivity in the temporo -parietal junction (TPJ) (Silbersweig, Stern et al. 
1995; Lawrie, Buechel et al. 2002). A recent provocative study has suggested that these abnormalities can be targeted by [CONTACT_50004] (tDCS) (Brunelin, Mondino et al. 2012) resulting in a significant decrease in auditory hallucinations that outlasts  stimulation for at least three months. However, the relative 
importance of the choices of stimulation parameters (stimulation waveform, number of treatments, treatment 
 
11 
 schedule) remains unknown. In particular, tDCS does not target the known deficits in the temporal structure of 
cortical network activity in patients with schizophrenia.  
2.2 RATIONALE  
Here, we propose a new innovative approach driven by [CONTACT_226236]- invasive brain 
stimulation to directly target the circuit -level patholog y of auditory hallucinations. Specifically, we will evaluate 
simultaneous tACS (10 Hz) to enhance synchronization between frontal and temporo -parietal areas of the left 
hemisphere. Such use of tACS to enhance synchronization has recently been introduced as  a successful modulator 
of long -range synchrony mediating working memory (Polania, Nitsche et al. 2012). Additionally, we will use EEG 
data to develop a novel biomarker to show that decreases in auditory hallucinations are predicted by [CONTACT_676267].  In the EEG analysis, we will also employ source 
localization techniques  to estimate the spatiotemporal dynamics of neuronal currents in the brain. In this step, we 
can minimize estimation errors o f the locations and strengths of the current sources in the brain by [CONTACT_676268] (sMRI). Because the 
source localization techniques can be problematic, small errors  in a source modeling step can lead to  larger errors 
in brain activity analysis. Anatomical brain structure and electrode location for each participant is are necessary components to get reliable and precise current sources in the brain. Ultimately, our go al is to treat patients based 
on demonstrable changes in brain activity, rather than on symptoms themselves. The proposed research is innovative because it employs a new form of non -invasive brain stimulation, tACS, which targets underlying 
functional neuropathology to treat medication refractory auditory hallucinations in schizophrenia. Additionally, we are developi[INVESTIGATOR_676246].  We recently completed a pi[INVESTIGATOR_676247] d to tDCS and sham for treating auditory hallucinations in patients 
with schizophrenia or schizoaffective disorder. Results from this study were negative with a strong placebo effect, however we found that tACS and sham showed lasting significant improvement of auditory hallucinations vs tDCS. Data collected in this study will be used to further understand the effect of tACS on auditory hallucinations and 
sustaining effects with maintenance sessions weekly for 2 months after the initial 5 days of stimulatio n.  
2.3 POTENTIAL RISKS AND BENEFITS  
 
2.3.1  KNOWN POTENTIAL RISKS  
Risk of Confidentiality Breach : In the unlikely event of a breach of confidentiality, people might discover that an 
individual was involved in this research study. This is especially sensi tive because the clinical population recruited 
for this study may be subjected to negative consequences caused by [CONTACT_456106]. Furthermore, 
some might not agree with the principle of participating in research or of changing natural brain  activity. To avoid 
breaches in confidentiality, study documents that contain personal information, including the informed consent 
document, and the document that links study ID numbers to personal identifying information are kept in locked 
filing cabinets  in a locked room, separate from any source documents containing participant dummy identifiers. All 
data is stored in locked cabinets inside locked offices; electronic data will be stored only on password -protected 
computers, and data encryption methods will be used during communication between investigators. Only study 
personnel will have access to these data. All study staff participate in annual human participant training that 
includes education about responsibilities to the minimize risk of confidential ity breach.   
 
12 
 Risk of Embarrassment : Self -reports and some assessments contain questions regarding sensitive personal 
information. This risk is necessary in order to assess experiences such as auditory hallucinations and disease state. 
Participants will be assured upon intake that only study personnel will see any clinical ratings, and study raters are trained to inquire about potentially distressing symptoms using a sensitive and respectful approach. Participants 
will be given the option not to answer quest ions that are too distressing.  
Risk of Injury and Discomfort : Transcranial current stimulation has been used without any reports of serious side -
effects for more than a decade. This stimulation mode has NOTHING to do with electroconvulsive therapy that 
applies many orders of magnitude higher stimulation current. Rather, transcranial current stimulation is so weak 
that it does not cause super -threshold activation of neurons (Frohlich and McCormick, 2010). In particular, tACS 
has been used without reports of  any serious side -effects. Some participants report a transient mild tingling, 
burning, or itching underneath the electrodes and headache, but no other side effects have been noted. Importantly, it remains unclear if these mild side -effects were caused by [CONTACT_226239]. In 
order to monitor these side- effects, we will be administering an adverse effects stimulation questionnaire 
(Attachments 1 &2) after each stimulation session to  document whether these effects were experienced. Research  
personnel present during these sessions will also check in with the participant periodically during the stimulation to see whether they are comfortable. If any side- effect occurs (rated by [CONTACT_226240] 
“moderate”) or the participant is  experiencing severe discomfort, the stimulation will be immediately stopped.  
While not previously reported with tDCS or tACS in humans, there is a theoretical possibility that stimulation of neuronal circuits could lead to epi[INVESTIGATOR_219601]. To minimi ze this occurrence, we screen and exclude patients 
with personal and family history of neurological conditions from the study. If abnormalities or a seizure is witnessed during the course of the study, the subject will be referred to a neurology clinic for  further evaluation 
and treatment.  
We have no evidence that our treatment paradigms will increase auditory hallucinations if not treated (receive the sham treatment), as participants, will be by [CONTACT_108], stable. If an enrolled patient shows signs of increase symptoms that were not apparent during enrollment, a referral to UNC Psychiatry will be made. [CONTACT_104654], Co -I, 
will facilitate this process.  
MR Scanning: Magnetic resonance scanning does not involve the use of ionizing radiation. There are no known risks from MR imaging. The FDA has categorized MRI up to 8.[ADDRESS_914278] (FDA approved) clinical  sequen ces to prevent harm to subjects. On very rare occasions, the individual 
may feel some eye discomfort. The scanning will be stopped if this occurs. These symptoms, if present, will subside shortly after leaving the magnet. In rare occasions the subject may experience claustrophobia. If this is the case, the scan will be discontinued immediately. In rare occasions subject may experience a localized twitching sensation due to the magnetic field changes during the scan. This is not unexpected and should not be painful. However, the 
subject can decide to stop the imaging session at any time if this occurs. Dizziness and nausea are also rare, and more often occur when the subject is moved quickly near the magnet or if the head is moved within the bore of 
the magnet. If the subject deems this sensation uncomfortable, the study will be terminated.  
2.3.[ADDRESS_914279] a clinical trial to provide further evidence for evaluation of the efficacy of tACS 
for treatment of  auditory hallucinations in patients with schizophrenia or schizoaffective disorder and explore the 
possible benefits of a maintenance regimen of 8 weekly sessions for prolonging symptom improvement.   As a 
secondary objective we will evaluate treatment effects on PANSS scores and BACS scores, and assess the 
differential clinical effects of sham and 10 Hz on EEG measures of alpha oscillations.  
Aim 1.  Evaluate the relative efficacy of the tACS treatment regimen and subsequent maintenance regimen in terms of changes in the mean level of the AHRS score  
Aim 2.  Evaluate the relative efficacy of the tACS treatment regimen and subsequent maintenance regimen in 
terms of changes in the mean levels of the PANSS score and the BACS score  
Aim 3.  Evaluate the effects of the tACS treatment regimen and subsequent maintenance regimen in terms of 
changes in EEG alpha frequency power levels.  
4 STUDY DESIGN   AND   OUTCOME MEASURES  
4.1 STUDY OUTCOME MEASURES   
4.1.1   PRIMARY OUTCOME MEASURES  
The Auditory Hallucination Rating Sc ale (AHRS) will be the primary outcome measure for this study. This survey 
instrument will be administered at the first recruitment visit, two weeks later at the screening visit, at baseline (t 0) 
on the first day of stimulation, after stimulation on the fifth day of stimulation (t 1), and at each of the 8 weekly 
maintenance sessions (t 2, t3,. t4, t5, t6, t7, t8, t9 ).  The primary analyses will focus on longitudinal changes from 
baseline in the AHRS scores at t 1 and t 9 accounting for the following explanatory variables:  treatment regimen, 
treatment stage (initial daily stimulation vs maintenance weekly stimulation), and the baseline AHRS score as a 
covariate.    
4.1.[ADDRESS_914280] day (t 0) and last day (t 1) of the 
stimulation week. We will also collect EEG data at the maintenance sessions at weeks 1, 3, and 8  (t2, t4, t9). We will 
use these data to analyze alpha frequency a ctivity for derivation of EEG biomarkers. Furthermore, we will estimate 
 
14 
 the locations and strengths of the current sources  in the brain using source localization techniques based on 
individual locations of scalp electrodes and anatomical structures. 
The Positive and Negative Syndrome Scale (PANSS) and Brief  Assessment of Cognition in Schizophrenia (BACS) will 
also be secondary outcome measures for this study. These measurements will be taken at the first day of 
stimulation  (t0), last day (t 1) of stimu lation and at the final maintenance stimulation visit  (t9). PANSS and BACS 
scores serve as measures of other positive, negative and general symptoms of schizophrenia (PANSS) or cognition 
(BACS). The analyses of these secondary measures will focus on longit udinal changes from baseline in the scores at 
t1 and t 9 accounting for treatment regimen, treatment stage( initial daily stimulation vs maintenance weekly 
stimulation), and the baseline AHRS score as a covariate.   
 
4.[ADDRESS_914281] 
preliminary efficacy data for use in further refinement of the tACS approach.  The experimental design is a 
randomized, two -treatment, multi -period, 4 -sequence crossover design.  The 40 enrolled participants will be 
allocated by a randomization protocol to for treatment -sequence groups:  tACS -tACS, tACS -sham, sham -sham, 
sham -tACS.   
The target population from which we are sampling is a clinica l population. W e are seeking [ADDRESS_914282] 12 weeks, meaning no 
change in the level of their care. The enrolled participants will be outpatients;  most will be referred through 
psychiatrists in the UNC Department of Psychiatry and affiliated ACT clinics, or by [CONTACT_676269].  We estimate [ADDRESS_914283] with a peak -to-peak amplitude of 2 mA. In each t reatment  regimen , participants will stay 
in a relaxed and controlled state by [CONTACT_84022] a nature movie such as “ReefScape” during stimulation.  The 
maintenance regimen will provide one 40- minute stimulation per week.  
 
[ADDRESS_914284] a total of 15 to 18 visits; an initial screening session, a 
2nd screening session, (if needed) [ADDRESS_914285] approximately 2 hours.  Maintenance stimulation sessions 
weeks 1 and 3 will be approximately 3 hours each, maintenance weeks 2, 4, 5, 6, and 7 will be approximately 2 hours each, and the  final maintenance stimulation session week 8 will be approximately 5 hours.  We estimate that 
total participant participation duration will be approximately 35 to 39 hours. A small subset of participants will be 
recruited for a 12 week observational case study to assess the feasibility of long -term at -home maintenance 
treatment.  
In order to ensure symptom stability for each potential participant, there will be up to a 6 week period for the participant to achieve a stable AHRS score. The AHRS will be performed at 2 week intervals during screening. A stable score is defined as having less than or equal to 20% change. If the change between the first and second AHRS scores is less than or equal to 20%, then the participant will move on to the week of stimulation. If a stable score is not achieved at the second screening session, the participant will have two more opportunities at 2 week intervals during follow -up screening sessions to achieve a stable score. The participant will be paid for each 
session. If the  participant does not achieve a stable score (if there remains a greater than 20% change in scores 
between consecutive AHRS administrations) by [CONTACT_2671] [ADDRESS_914286] meet all of the following criteria:  
• DSM -IV diagnosis of schizophrenia, any subtype, or schizoaffective disorder, with refractory auditory 
hallucinations. Duration of illness >1 year.  
• 18 – 70 years old  
• Clinically stable for at least 12 weeks i.e. not requiring hospi[INVESTIGATOR_26109] a change in level of care.  
• On current antipsychotic doses  for at least 4 weeks  
• Experience at last 3 auditory hal lucinations per week  
• Stable auditory hallucinations as demonstrated by [CONTACT_226242] 20% change in AHRS scores 
across a 2 week interval during the screening period  
• Capacity  to understand all relevant risks and potential benefits of the study and to provide written 
informed consent, OR has a legal guardian who can provide informed consent on the patient’s behalf with 
the patient providing written assent to participate   
5.2 PARTICIPANT  EXCLUSION CRITERIA  
A potential participant who meets any of the following criteria will be excluded from participation in this study:  
 
16 
 • DSM -IV diagnosis of alcohol or substance abuse (other than nicotine) within the last month o r a DSM -IV 
diagnosis of alcohol or substance dependence (other than nicotine) within the last 3  months  
• Positive urine test of cannabis, cocaine, amphetamine, barbiturates, opi[INVESTIGATOR_858]  
• Current treatment (within 4 weeks) with psychotropic agents including benzodiazepi[INVESTIGATOR_676248] 
a daily basis (limit prn use to greater than 48 hours befor e participating in study session)  
• Medical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or renal impairment) or 
treatment for a medical disorder that could interfere with study participation  
• History of traumatic brain injury that required subsequent cognitive rehabilitation, or cause cognitive 
sequelae  
• A difference greater than 20% in AHRS scores between the 3rd and 4th screening visits  
• Prior brain surgery  
• Any brain devices/implants, including cochlear implants and aneurysm cli ps 
• Co-morbid neurological condition (e.g. seizure disorder, brain tumor)  
• Non English speakers  
• Female participants who are pregnant, nursing, or unwilling to use an adequate method of contraception 
during study participation for those of child bearing potential  
• Anything that, in the opi[INVESTIGATOR_871], would place the participant at increased risk or preclude 
the participant’s likelihood of completing all components of the study  
 
5.[ADDRESS_914287] team. Providers will include the medical teams treating patients at either of the two locations (Chapel Hill or Rale igh). Providers will identify patients they believe to be appropriate for this 
study based on the information we will provide them about the study. Providers will ask patients whether they are willing to be contact[CONTACT_676270]. Providers will be asked to avoid unnecessary 
medication changes leading up to and over the course of the study.  
Our retention strategy includes monetary compensation for the time and effort required to participate in the study. The participant will  receive a payment at each session of the study. The research staff will also give each 
participant a reminder call for the initial screening session, each follow up screening session, the first day of stimulation, and each maintenance session. Each resear ch staff member will be easily available for the participants 
to contact [CONTACT_187931]. The inclusion criteria state that each participant must be able to understand all risks and benefits associated with this study. We will be asking each participant  to answer questions about the consent 
form to  verify  that the study process and the duration of participation are completely understood by [CONTACT_93502]. We will aim to have a specific research team member assigned to complete all sessions with the same 
 
[ADDRESS_914288] at forming a professional relationship with the participants so they feel 
comfortable and willing to discuss what may be sensitive information. Retention will b e quantified by [CONTACT_676271] (the data from each session will be scored and documented the day of the session). Participants will no longer be eligible to continue the study if they miss 2 consecutive stimulation session s 
during the initial week of stimulation, if they miss 2 consecutive weeks of stimulation during the maintenance sessions, or if they miss more than 2 non -consecutive sessions during the course of the study.  While we will ask 
each participant to complete an sMRI visit, it is not necessary for this visit to occur. If the participant does not want 
to complete the sMRI visit, the participant will be eligible to continue the remainder of the study.  
5.4 PARTICIPANT  WITHDRAWAL  OR TERMINATION  
5.4.1  REASONS FOR WI THDRAWAL  OR TERMINATION  
A study participant will be discontinued from further participation if:  
• The participant has missed more than 2 non- consecutive stimulation sessions  
• The participant has missed 2 consecutive stimulation sessions during the initial wee k of stimulation  
• The participant has missed 2 consecutive weeks of stimulation during the maintenance sessions  
• Any clinical adverse event (AE), laboratory abnormality, intercurrent illness or other medical condition, or 
situation occurs such that continued participation in the study would not be in the best interest of the participant.  
• The participant meets any ex clusion criteria (either newly developed or not previously recognized)  
• A participant wishes to withdraw from further participation for any reason  
5.4.[ADDRESS_914289] safety data on any participant discon tinued because of an AE or SAE.  In any case, every effort will 
be made to undertake protocol -specified safety follow- up procedures.  If voluntary withdrawal occurs, the 
participant will be asked to continue scheduled evaluations and complete an end- of-study evaluation.  If an AE has 
been reported, researchers will help the participant seek the medical care they need and a follow up will be 
performed by [CONTACT_978] [INVESTIGATOR_12749] -I.   
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY  
This study may be prematurely terminat ed if, in the opi[INVESTIGATOR_871], there is sufficient reasonable 
cause.  Circumstances that may warrant termination i nclude, but are not limited to:  
● Discovery of unexpected, significant, or unacceptable risk to participants.  
● Insufficient adherence  to protocol requirements.  
● Data that are not sufficiently complete and/or evaluable.  
● Plans to modify , suspend or discontinue the development of the study device.  
The IRB will be informed promptly and provided the reason(s) for the termination or suspension by [CONTACT_171372]/institution, as specified by [CONTACT_8146](s).  
 
 
[ADDRESS_914290] DESCRIPTION  
6.1.1  DEVICE DESCRIPTION  
Participants will be stimulated with the commercial, CE -certified Neuroconn Plus stimulator .The use of this device 
in this study has previously received a NSR designation on initial review by [CONTACT_61598]. The NeuroConn device 
description is as follows:  
The DC -STIMULATOR is a CE -certified medical device for conducting non- invasive transcranial direct -current 
stimulation (tDCS) in humans. DC stimulation is used in clinical practice and in the research of stroke, epi[INVESTIGATOR_002], migraine, tinnitus, depression, multiple sclerosis, dementia and chronic headache. The DC -STIMULATOR is a micro -
processor -controlled constant current source. It meets the highest safety standards thanks to (hardware - and 
software- based) multistage monitoring of the current path. By [CONTACT_676272], maximizing  patient safety.  
The device's alphanumeric display and the 4 touch keys allow various stimulation modes to be selected and stimulation parameters such as current strength, duration, fade -in and fade -out to be set.  
DC-STIMULATOR features:  
• 1 channel (anodal and cathodal stimulation possible)  
• Adjustable current up to 5,000 µA *  
• Adjustable application time up to 30 minutes *  
• [ADDRESS_914291] modes - single (continuous stimulation) and - pulse (cyclical stimulation 
activation/deactivation) with fade in and fade out  
• Customer -specific programs possible (optional)  
• "Study mode" for blind processing of genuine and 'pseudo' stimulation (optional)  
• External trigger input ( optional)  
 
6.1.[ADDRESS_914292] the stimulant from high currents.  The stages are as follows:  
1. Automatic software current cutoff.  The output of the current sensor described above is read by a 
microprocessor, which compares the reading to a value of +/ -3mA peak.  If the current exceeds these 
limits, stimulation is stopped, a relay in series with the electrode is opened, and the power supply used 
for s timulation is turned off.  The user is then given the option to investigate the issue, and cancel or 
resume the test.  Since high -side current sensing is used (described above), any short circuit of the 
electrode terminals to ground will be detected.  
2. Automatic hardware current cutoff.  The output of the current sensor is fed into a pair of comparators 
which detect if the current exceeds +/ -4.5mA.  If so, the fault is latched such that the relay in series with 
the electrodes is opened.  Additionally, the microprocessor is notified of this instance through an interrupt.  Upon this interrupt, the microprocessor immediately stops stimulation and the power supply 
used for stimulation is turned off.  
Figure 1: Example of successful hardware cutoff function  
 

 
[ADDRESS_914293] -acting fuse is in series with the electrode connector.  If 
the above two over -current detection methods fail, the fuse will blow, and the stimulant will no longer be 
electrically connected to the device.  
4. Power supply fuse.  Finally, if for any other reason the entire device draws too much current, the main 
power supply fuse is blown.  This fuse is sized with a cutoff of 200% of steady -state operating current. 
Digitizing scanner  
We will be using a GeoScan digitizing scanner to scan individual locations of scalp EEG electrodes. The GeoScan 
handheld digitizing scanner integrates into OEM neurodiagnostic equipment to measure, identify, and map electrode positions (via attached markers). This is based on optical 3D measurement technology that scans up to 256 markers in less than 2 minutes to accuracy within 0.5 mm and repeatability of 0.1 mm. Real -time 
compensation for data variability ensures only actual markers are measured for mappi[INVESTIGATOR_676249] s. 
GeoScan Digitizing Scanner  
• Features  
Scanner Specifications  
Dimensions (LxWxH)  155 mm x 75 mm x 300 mm  
Weight  860 g  
Power Requirements  100- 250 V AC ~50/60 Hz, 1 A  
Sensor Specifications  
Measurement Volume  883 mm x 840 mm x 928 mm  
Update Frequency  20, 30, 60 Hz  
Scan Rate  256 markers < [ADDRESS_914294] Edition  

 
21 
  
• Operation  
   
1. Attach each electrode 
(with prefixed marker) to 
the scalp or cap.  2. Scan the head with the 
device  to localize each 
marker’s position. This 
localization process 
creates a digital point 
cloud (3D model) and rigid body of marker 
coordinates.  3. Probe anatomical 
features to establish fiducial  (reference) 
points with respect to 
the rigid body, such as 
the nasion, inion, and preauricular points of 
the subject’s head.  
 
 
7 STUDY PROCEDURES/EVALUATIONS  
7.[ADDRESS_914295]. 
Several clinical evaluations will be used througho ut this study. These assessments are listed below and can be 
found in the attached documents.  
i. The Structured Clinical Interview for DSM -IV Axis I Disorders (SCID- I) is a semi -structured interview 
used to diagnosis major Axis I disorders. For this study, the SCID -I (First et al. 2004) will be 
administered at baseline in order to confirm a diagnosis of Schizophrenia or Schizoaffective Disorder.  
ii. The Columbia Suicide Severity Rating Scale  (C-SSRS) is a semi -structured interview designed to assess 
suicidality. The assessment  will be administered at baseline, the first day of stimulation, the fourth 
main tenance stimulation session, and the final maintenance stimulation session.  
iii. The Auditory Hallucination Rating Scale (AHRS) is a structured interview, designed to assess different 
aspects of patient’s auditory hallucinations. This assessment has 11 items a nd is rated on a scale of 0 
– [ADDRESS_914296] day of stimulation, and at each of the maintenance stimulation sessions.  
iv. The Positive and Negative Syndrome Scale (PANSS) is a structured interview used to assess the symptom severity of patients diagnosed with schizophrenia. The PANSS (Kay et al. 1987) focuses on the positive and negative syndromes and their general severity. This scale will be administered at the 

 
[ADDRESS_914297] day of stimulation and at the final maintenance stimulation session 
(week 8).  
v. The Brief Assessment of Cognition in Schizophrenia (BACS) will be administered at the first d ay of 
stimulation, the last day of stimulation and at the final maintenance stimulation session (week 8) in order to monitor changes in participant cognition. This validated assessment (Keefe et al. 2004, Keefe et al. 2006) contains 6 tests that focus on v erbal memory and learning, working memory, motor 
functioning, attention/processing speed, verbal fluency and reasoning and problem solving.  
7.[ADDRESS_914298] data on participant experience. A similar questionnaire was used in IRB #13- 2995, #14- 3285, and # 14-1622 to evaluate ability to successfully 
blind using transcranial current stimulation.  (Attachment 1 and Attachment 2) .  
7.3 LABORATORY PROCEDURES/EVALUATION S 
 
7.3.[ADDRESS_914299] 
will also be performed prior to the sMRI scan, and at each maintenance sessions for women of child -bearing 
potential.  
7.3.2 OTHER ASSAYS OR PROCEDURES  
The Brief Assessment of Cognition in Schizophrenia (BACS) (Attachment 6 ) will be administered during the 1st day 
of stimulation, the 5th day of stimulation and at the final maintenance stimulation session (week 8). This assay was 
specifically designed to assess cognition in patients diagnosed with schizophrenia and will be used to obtain a baseline assessment of cognition in each participa nt. We will also be using this assay as a safety monitor and data 
collection tool throughout the study to assess any changes in cognition that may be seen as a result of the 
treatment.  
There will be two procedures used throughout this study. Each participant will attend 5 consecutive weekdays of 
stimulation for this study. Each participant will be randomly assigned to one of four  treatment -sequence groups  
for this study (sham or 10HZ tACS). Electrodes with a measurement of 5x5cm will be placed between Fp1 and F3 and between T3 and P3, and a return electrode, 5x7cm, will be placed over Cz. In order to detect any change(s) at the neurophysiological level, an EEG will be performed during the [ADDRESS_914300] individual locations of EEG 
 
23 
 electrodes using a digitizer(GeoScan)  and structural MRI (sMRI) for each par ticipant that is willing/able to safely 
complete an sMRI scan. These two additional information can help to make a well -constructed head model and 
source model for reconstructing location and the time -course or spectral content of a source in the brain. Th e 
electrode localization scanning using the GeoScan will be applied at each EEG recording, as there is the possibility 
for slight changes in electrode location at each EEG net application. As the structure of the brain will not change over the course of pa rticipation, the electrode localization for each EEG recording will be applied to the sMRI 
image to make the head model.  
During each EEG recording, we will also be collecting ECG  data. These ECG  electrodes will be a part of the EEG 
acquisition system and will be placed on the participant’s  body, ideally one electrode below the right collarbone 
and a second one below the chest on the left . This data will be collected to look at HRV across conditions.  
7.[ADDRESS_914301] log for each telephone conversation with a participant 
throughout the study. There will be a log for each participant .  
During the telephone screening, researchers will provide a brief background about Schizophrenia and tACS.  Any 
initial questions will be answered at this point. The timeline of visits will then be explained ; there will be [ADDRESS_914302] been a nswered, the participant will be asked if he/she is still interesting in participating in 
the study.  If yes, the researcher will begin the initial phone screening which will determine eligibility for the initial session. The screening questions are shown below. If the required answers are given for each question, the initial session will be scheduled and a reminder call will be given at least 24 hours before initial session. We will use the approved telephone script for all telephone screenings.  
 
7.4.2 ENROLLMENT/BASELINE 
Initial Screening Visit (Visit 1, Day 0)  
At the consent visit,  participants will go over the consent form mailed to their address and all questions will be 
answered before they document their consent through a REDCap eConsent form. Each f orm will be read to the 
participant by [CONTACT_3021], and the participant will be given the time to ask any questions about the information discussed. Each participant will be asked a series of questions ( Appendix E ) to ensure that the consent form is ful ly 
understood. Participants will physically sign both a HIPAA authorization form and the consent form  to be mailed 
back to the researcher or brought to the first lab visit . The researcher will verify that the participant meets 
inclusion criteria. Next, the  SCID (Attachment 4) will be administered in order to confirm diagnosis of schizophrenia 
or schizoaffective disorder and to verify that the participant does not have active alcohol or illicit drug abuse or dependency.  The participant will be asked to provi de verbal consent to record their SCID interview. They may 
 
24 
 decline the recording and continue in the study.  The C -SSRS (screening version) will be administered next. If a 
participant answers 'yes' to items 3, 4, or [ADDRESS_914303] month or answers 'yes' to 
any suicidal behavior within the past six months, the study coordinator will call [CONTACT_104654], who will determine if 
an acute assessment is needed. [CONTACT_104654] will conduct this acute assessment if it is needed.  Once the dia gnosis 
has been confirmed,  a baseline Auditory Hallucinations Rating Scale (AHRS) will be administered to document 
hallucinatory severity and frequency. Demographic information will be collected, which will include a history of 
medication, alcohol, and dru g use. A short handedness questionnaire , a Belief about Treatments questionnaire, 
the BIS/BAS scale , and the HPSVQ will also be  self administered  via REDCap survey . The 2nd screening visit will be 
scheduled for approximately 2 weeks later . The participant’s payment will be placed in an envelope to be mailed 
after the screenings are completed or distributed at the first lab visit.  
2nd Screening Visit (Visit 2)  
The 2nd screen ing visit will also take place over webex . The following questionnaires will then be administered to 
further check eligibility; Auditory Hallucination Rating Scale (AHRS) in order to document any change in auditory hallucination severity/frequency ( Attachm ent 3 ). The AHRS scores from the initial screening visit and the current 
visit will be compared. If a change in score greater than 20% exists, then a 3
rd screening visit will be scheduled for 
approximately 2 weeks later. If a change in AHRS score is less than or equal to 20% and eligibility has been confirmed, the week of stimulation will be scheduled . The participant’s payment will be placed in the original 
envelope to be mailed after the screenings are completed or distributed at the first lab visit.  
3
rd Screening Visit (Possible Visit 3)  
The 3rd screening visit will also take place over webex . The following questionnaires will then be administered to 
further check eligibility; Auditory Hallucination Rating Scale (AHRS) in order to document any change in a uditory 
hallucination severity/frequency ( Attachment 3 ). The AHRS scores from the 2nd screening visit and the current visit 
will be compared. If a change in score greater than 20% exists, then a 4th screening visit will be scheduled for 
approximately 2 weeks later. If a change in AHRS score is less than or equal to 20% and eligibility has been confirmed, the week of stimulation will be scheduled . The participant’s payment will be placed in the original 
envelope to be mailed after the screenings are completed or distributed at the first lab visit.  
4
th Screening Visit (Possible Visit 4)  
The 4th screening visit will also take place over webex. The following questionnaires will then be administered to 
further check eligibility; Auditory Hallucination Rating Sca le (AHRS) in order to document any change in auditory 
hallucination severity/frequency ( Attachment 3 ). The AHRS scores from the 2nd screening visit and the current visit 
will be compared. If a change in score greater than 20% exists, then the participant is considered not eligible to 
participate and will be paid for completing the session. If a change in AHRS score is less than or equal to 20% and eligibility has been confirmed, the week of stimulation will be scheduled . If the participant is considered not  
eligible to participate, their payment will be placed in the original envelope to be mailed. If they are eligible the 
payment will be added to the original envelope to be distributed at the first lab visit .  
7.4.3 STIMULATION WEEK  
Day 1 of Stimulation (Visit 5)  
Upon participant arrival , a completed consent form and HIPAA authorization will be confirmed to be in the 
participant file. All participants (male and female) will be asked to complete a urine drug screening to determine 
eligibility f or the study. Female participants will complete a urine pregnancy test to rule -out pregnancy. V ital signs 
 
25 
 will be taken . The C -SSRS (screening version) will be administered next. If a participant answers 'yes' to items 3, 4, 
or 5 in the suicidal ideation s ection or answers 'yes' to any suicidal behavior since the initial screening visit , the 
study coordinator will call [CONTACT_104654], who will determine if an acute assessment is needed. [CONTACT_104654] will 
conduct this acute assessment if it is needed.  Then, the AHRS (Attachment 3 ) will be administered followed by [CONTACT_676273] (Attachment 5 ) and the Brief Assessment of Cognition in Schizophrenia (BACS) (Attachment 6). The BACS 
will be used as a baseline assessment of participant cognition, and will be administered again during later sessions to assess for any changes in cognitive function associated with treatment . An EEG will then be administered, with 
ECG data also being collected at this time. The EEG recording will include resting state data along with an auditory  
task, and the EEG Questionnaire will be administered.  
Once the questionnaires are complete, the participant will be administered either sham or 10 Hz tACS treatment for 40-minutes . Participants will be asked to sit still and not talk during these 40- minutes , and will be asked to keep 
their eyes open and facing straight ahead. The Reefscape video will be played during the stimulation session.  After 
each stimulation treatment, to assess any side effects of stimulation, the stimulation adverse effects questi onnaire 
will be administered. This questionnaire will be administered at the end of each stimulation session as a safety assessment to monitor any potential side effects of the stimulation ( Attachment 1 ). Participants will be paid  for 
this visit as well as  all previous screenings  at the conclusion of this session.   
Days 2 – 4 of Stimulation (Visit 6 – 8) 
Upon participant arrival, vital signs will be taken . The participant will then receive 40 -minutes  of sham or 10 Hz 
tACS (as per the initial randomization)  while sitting quietly with their eyes open. The Reefscape video will be played 
during each stimulation session.  Each stimulation session will be followed by [CONTACT_676274]. Participants will be paid at the conclusion of each  session.   
Day 5 of Stimulation (Visit 9)  
The participant will be asked to decide if they would like to complete the clinical assessments over the phone or in person. If they prefer the phone/webex, the participant will be contact[CONTACT_676275] t he AHRS 
(Attachment 3 ) and PANSS (Attachment 5 ) will be administered. Upon participant arrival  at the lab , vital signs will 
be taken and documented at the beginning of the first stimulation session of the day.  An EEG will then be administered , with ECG  data also being collected at this time. The EEG recording will include resting state data 
along with an auditory task, and the EEG Questionnaire will be administered. The participant will receive 40 -
minutes  of sham or 10 Hz tACS (as per the init ial randomization) while sitting quietly with their eyes open. The 
Reefscape video will be played during the stimulation session. Each stimulation session will be followed by [CONTACT_676276].  The BACS (Attachment 6) data colle ction assessments will be 
administered at the end of this session . If the participant opted to complete the clinical assessments in person, the  
AHRS (Attachment 3 ) and the PANSS (Attachment 5 ) will be administered at the end of this session. After the 
assessments are completed, the participant will then be paid at the completion of the session, and the first 
maintenance session will be scheduled for the second week after their last day of stimulation (one gap week in 
between).  
7.4.4  STRUCTURAL MRI VISIT  
sMRI Scan Visit (Visit 10)  
During the gap week between the 5th day of stimulation and the 1st maintenance session, we will ask the 
participant to come in and complete an sMRI scan.  MRI scan imaging will take place at the Biomedical Research 
 
26 
 Imaging Center (BRIC), located in Marsico Hall on the first floor.  If the participant is a female of child -bearing 
potential, they will be asked to complete a urine pregnancy test prior to completing the scan. Screening questions 
asked prior to the MRI scan  (Attac hment 8 ) and all preparation for scans will take place in a facility area behind a 
locked door, where only research study personnel have access. When subjects are required to change their 
clothing, they will be allowed to do so alone, in a room with a door  that locks. MRI scan will be performed by 
[CONTACT_676277] [INVESTIGATOR_676250].  
 
7.4.5 MAINTENANCE SESSIONS  
Maintenance Stimulation Session Week 1 (Visit 1 1) 
Upon participant arrival, vital signs will be taken and documented. Female participants will complete a urine 
pregnancy test to rule -out pregnancy. An EEG will then be administered, with ECG data also being collected at this 
time. The EEG recording will in clude resting state data along with an auditory task, and the EEG Questionnaire will 
be administered. The participant will receive 40 -minutes  of sham or 10 Hz tACS (as per the randomization) while 
sitting quietly with their eyes open. The stimulation sessi on will be followed by [CONTACT_676274]. The AHRS and HPSVQ will then be administered to assess severity of auditory hallucinations.  Participants will be paid at the conclusion of this study visit, and the next study visit will be scheduled for the 
following week.  
Maintenance Stimulation Session Week 2 (Visit 1 2) 
Upon participant arrival, vital signs will be taken and documented. Female participants will complete a urine 
pregnancy test to rule -out pregnancy. An EEG will then be  administered, with ECG data also being collected at this 
time. The EEG recording will include resting state data along with an auditory task, and the EEG Questionnaire will be administered. The participant will receive 40 -minutes  of sham or 10 Hz tACS (as  per the randomization) while 
sitting quietly with their eyes open. The stimulation session will be followed by [CONTACT_226251]. The AHRS and HPSVQ will then be administered to assess severity of auditory hallucinations.  Participants will be paid at the conclusion of this study visit, and the next study visit will be scheduled for the 
following week.  
Maintenance Stimulation Session Week 3 (Visit 1 3) 
Upon participant arrival, vital signs will be taken and documented . Female par ticipants will complete a urine 
pregnancy test to rule -out pregnancy. The C -SSRS ( follow -up version) will be administered next. If a participant 
answers 'yes' to items 3, 4, or 5 in the suicidal ideation section or answers 'yes' to any suicidal behavior si nce the 
week of stimulation , the study coordinator will call [CONTACT_104654], who will determine if an acute assessment is 
needed. [CONTACT_104654] will conduct this acute assessment if it is needed.  An EEG will then be administered, with ECG  
data also being collected at this time. The EEG recording will include resting state data along with an auditory task, and the EEG Questionnaire will be administered. The participant will receive 40- minutes  of sham or 10 Hz tACS (as 
per the randomization)  while sitting quietly with their eyes open. The stimulation session will be followed by [CONTACT_676276]. The AHRS and HPSVQ will then be administered to assess severity of auditory hallucinations.  Participants will be paid at  the conclusion of this study visit, and the next study visit will be 
scheduled for the following week.  
Maintenance Stimulation Session Week 4-7 (Visits 1 4-17) 
Upon participant arrival, vital signs will be taken and documented. Female participants will co mplete a urine 
pregnancy test to rule -out pregnancy. The participant will receive 40 -minutes  of sham or 10 Hz tACS (as per the 
randomization) while sitting quietly with their eyes open. The stimulation session will be followed by [CONTACT_941] 
 
27 
 stimulation adverse effects questionnaire. The AHRS and HPSVQ will then be administered to assess severity of 
auditory hallucinations.  Participants will be paid at the conclusion of this study visit, and the next study visit will be 
scheduled for the following week.  
7.4.6 FINA L STUDY VISIT  
Maintenance Stimulation Visit Week 8 (Visit 1 8) 
Upon participant arrival, vital signs will be taken and documented.  Female participants will complete a urine 
pregnancy test to rule -out pregnancy. The C -SSRS ( follow -up version) will be adminis tered next. If a participant 
answers 'yes' to items 3, 4, or 5 in the suicidal ideation section or answers 'yes' to any suicidal behavior since the third week of maintenance, the study coordinator will call [CONTACT_104654], who will determine if an acute asses sment is 
needed. [CONTACT_104654] will conduct this acute assessment if it is needed.  An EEG will then be administered, with ECG  
data also being collected at this time. The EEG recording will include resting state data along with two auditory tasks, and the EEG  Questionnaire will be administered. The participant will receive 40 -minutes  of sham or 10 Hz 
tACS (as per the randomization) while sitting quietly with their eyes open. After the session participants will 
complete the stimulation adverse effects questionnaire. The AHRS and HPSVQ will be administered to assess severity of auditory hallucinations, followed by [CONTACT_676278] a review of current 
medications. The PANSS ( Attachment 5 ), and BACS (Attachment 6) data collection assessments will be 
administered at the end of this session for endpoint assessment. Each participant will be asked whether they 
believe their symptoms have changed (better, worse, no change) over the course of the study. After the 
assessm ents are completed, the participant will then be paid for the completion of the final study visit.   
7.4.7  CASE STUDY  
 
Case Study  
A subset of participants (up to 4) will be recruited from the original participant pool for a 12- week case study 
evaluating the  feasibility of long- term maintenance. Participants will self- identify as being interested, and the PI 
[INVESTIGATOR_529926] -Is will then determine eligibility. Participants will receive [ADDRESS_914304] included maintenance sessions in the study schedule in order to examine lasting effects of tACS. After the 
final maintenance session, no further treatment will be offered.   
 
8 ASSESSMENT OF SAFETY  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS Procedures  Initial Visit via 
webex  Screening Visit 
(2-4) via 
webex  Day 1 of Stimulation  Days 2 -4 of 
Stimulation  Day 5 of Stimulation  sMRI Visit  Maintenance 
Stimulation 
(Week 1)  Maintenance 
Stimulation 
(Week 2)  Maintenance 
Stimulation 
(Week 3)  Maintenance Stimulation 
(Weeks 4 – 7) Maintenance 
Stimulation 
(Week 8)  
eConsent REDCap  X           
Signed Consent Form    X         
SCID  X           
C-SSRS  X  X      X  X 
Demographics  X           
Med History  X           
Medications  X-------------------------------------------------------------------------------------------------------------------------------------------- X 
Handedness  X           
Beliefs about Tx  X           
BAS/BIS  X           
AHRS  X X X  X  X---------------------------------------------------------------------X 
HPSVQ  X X X  X  X---------------------------------------------------------------------X 
Vital Signs    X-----------------X  X---------------------------------------------------------------------X 
Pregnancy test    X   X X---------------------------------------------------------------------X 
Urine Drug Screen    X         
PANSS    X  X      X 
BACS    X  X      X 
Randomization    X    X     
Stimulation    X X X  X---------------------------------------------------------------------X 
EEG   X  X  X  X  X 
EEG Questionnaire    X  X  X  X  X 
AE  Interview    X------------------- X  X---------------------------------------------------------------------X 
Sx improvement Q’s      X  X---------------------------------------------------------------------X 
sMRI       X      
HRV   X  X  X  X  X 
 
[ADDRESS_914305] any changes in these symptoms; additionally we did not find any 
changes in related clinical trials (IRB# 13 -2995, IRB #14- 3285).  Should there be a significant change in PANSS rating 
scores, (>25% increase) we will direct the participant to [CONTACT_104654] for further follow up and file a AE report.  
The Columbia Suicide Severity Rating Scale will be administered at the initial session and roughly monthly intervals 
thereafter. The tool is used to assess recent and lifetime suicidality and will primarily determine if [CONTACT_104654] should be called to con duct an acute assessment. Should a participant answer “yes” to items 3,4, or 5 on the 
Suicidal Ideation section or “yes” to any Suicidal Behavior question within a recent time period (specified above), 
[CONTACT_104654] will be called to conduct an acute assessm ent and we will file an AE report.  
After each stimulation session, a stimulation adverse effects questionnaire ( Attachment 1and Attachment 2)  will 
be administered.  This tool is used to document any side effects experienced during stimulation. The researc her 
will also check with the participant throughout the 20 minute stimulation sessions to make certain no discomfort is 
felt.  The stimulation session will be terminated if the participant reports having unmanageable discomfort or pain (more than “moderate ”).  Additionally, this information will be reported on an AE report form (Appendix A ) and an 
AE log (Appendix B). 
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  
Adverse Event:   An AE, as defined by [CONTACT_18121], is any unfavorable changes in health, including /abnorm al laboratory 
findings that occur in trial participants during the clinical trial or within a specified period following the trial.  
 
All AEs including local and systemic reactions not meeting the criteria for “serious adverse events” will be captured 
on the appropriate CRF.  In addition, the AE Interview will be completed by [CONTACT_676279] (see attachment ).  For any Adverse events reported, a clinician will evaluate and indicate the severity of the 
event(s). The AE report form ( Appendix A) will be completed for any reported AE. The AE form includes the 
following:  what is known about the therapy and previous reported side effects, if the AE occurred in temporal 
relation to the therapy, whether or not the AE improves or disappears when treatment is stopped, whether the AE is a worsening of baseline symptoms or related to a concurrent medical condition or medication use. Once complete, both of these form s will be given to the PI [INVESTIGATOR_79761] -I who will review, comment and sign th e forms .  
Completed forms will be placed in the participant’s folder.   
The study coordinator will document any AE occurrence on the AE log ( Appendix B ) which includes information 
such as the date of the AE, severity, relationship to the treatment (assessed by [CONTACT_978]), actions taken, and 
outcome(s). The log will be reviewed and initialed by [CONTACT_978] 72 hours after being completed. All AEs occurring during the clinical trial will be documented appropriately regardless of relationship to tACS. All AEs will be f ollowed 
to adequate resolution and will be graded for severity and relationship to the study treatment.  Any medical 
condition noted at the initial session will be considered as base line and not reported as an AE.  
All AEs will be graded for severity using the following guidelines.  
 
30 
 ● Asymptomatic:  the participant is exhibiting no symptoms due to the event; no treatment needed.  
● Mild  Adverse Event – Event results in mild or transient discomfort, not requiring intervention or 
treatment; does not limit or interfer e with daily activities (e.g., insomnia, mild headache).  
● Moderate  Adverse Event – Event is sufficiently discomforting so as to limit or interfere with daily 
activities; may require interventional treatment (e.g., fever requiring antipyretic medication).  In the 
case of a moderate adverse event the medical advisor may recommend an over the counter medication.  
● Severe and undesirable  Adverse Event – Event results in significant symptoms that prevents normal 
daily activities; may require hospi[INVESTIGATOR_84006] (e.g., anemia resulting in blood transfusion).  
Changes in the severity of an AE will be documented with the Note to File document ( Appendix G) and will be filed 
in the participant’s folder.  
8.1.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE) 
Serious Adverse Event (SAE):  An SAE, as defined by [CONTACT_18121], consists of adverse events that result in death, require 
either inpatient hospi[INVESTIGATOR_84007], are life -threatening, result in a persistent or 
significant disability/incapacity or result in congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant’s 
health is at risk and intervention is required t o prevent an outcome mentioned.  
All SAEs will be recorded on the Serious Adverse Events Form ( Appendix C ), documented in the UE/SAE log and 
reported to the IRB. The SAE Form will be completed by [CONTACT_9137], and includes information relating to 
the onset and nature of the SAE, relationship to the study treatment, seriousness of the SAE, treatment required as a response to the SAE, and outcome. This form will be filed in the participant’s binder at the resolution of the event. The study coordinato r will complete the UE/SAE log ( Appendix D) which includes information such as the 
date of the event, time at which the study team was informed of the event, details, when the IRB has been 
notified, and the date that the SAE Form was completed.  
8.1.3  DEFINITION OF UNANTICIPATED PROBLEMS (UP)  
Unexpected Events (UE) will be recorded on the UE/SAE log ( Appendix D) and will include information including 
date of the event, when the study team was informed of this event, event details, when the IRB was notified, and 
whether the SAE Form was completed. The IRB will be notified of each UE that may occur during the study.  
The Office for Human Research Protec tions considers unanticipated problems involving risks to participants or 
others to include, in general, any incident, experience, or outcome that meets all  of the following criteria:  
● Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol -related documents, such as the IRB -approved research protocol and informed 
consent document; and (b) the characteristics of the participant population being studied;  
● Related or possibly related to participation in the research  
● Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
 
[ADDRESS_914306] the health and safety of 
the participants. Depending on the nature of the UE, the research protocol, inclusion/exclusion criteria, and informed consent will be changed to reflect the possibility of this event  reoccurring. During this time, no new 
participants will be recruited and the research procedures for currently enrolled participants will be stopped. Each UE will be recorded and reported throughout the study.   
 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  
 
8.2.1  SEVERITY OF EVENT  
All AEs will be graded for severity using the following guidelines.  
● Asymptomatic:  the participant is exhibiting no symptoms due to the event; no treatment needed.  
● Mild  AE– Event results in mild or transient discomfort, not requiring i ntervention or treatment; does 
not limit or interfere with daily activities (e.g., insomnia, mild headache).  
● Modera te AE – Event is sufficiently discomforting so as to limit or interfere with daily activities; may 
require interventional treatment (e.g., fever requiring antipyretic medication).  In the case of a moderate adverse event the medical advisor may recommend an over the counter medication.  
● Severe and undesirable  AE – Event results in significant symptoms that prevents normal daily 
activities; may require hospi[INVESTIGATOR_84006] (e.g., anemia resulting in blood transfusion).  
Changes in the severity of an AE will be documented with the Note to File document ( Appendix G ) and will be filed 
in the participant’s folder.  
8.2.2  RELATIONSHIP TO STUDY AGENT  
The PI [INVESTIGATOR_7706] -I will together determine whether an AE is associated with the study treatment. The event will be 
labeled associated if the event is temporally related to the administration of the therapy and no other factors can explain the event. The event will be labeled as not associated if the event is temporally independent of the study 
treatment and can be explained by [CONTACT_676280].  
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
Medical monitor/Co -I will follow up with participants within one week of an AE.  
8.4 REPORTING PROCEDURES  
We will be adopting the following procedures for reporting procedures:  
What Event is Reported  When is Event Reported  By [CONTACT_676281] -threatening 
unexpected, suspected Within  24 hours  of initial receipt of 
information  Investigator  ● Local/internal IRBs, 
DSMB  
 
32 
 serious adverse 
reactions        
Non -fatal, non -life-
threatening unexpected, 
suspected serious 
adverse reactions  Within  48 hours of initial receipt of 
information  Study 
Coordinator  ● Local/internal 
IRBs/Institutional 
Officials, DSMB  
Unanticipated adverse 
device effects  Within  [ADDRESS_914307]  Investigator  ● Local/internal IRBs  
 
Unanticipated Problem 
that is not an SAE  Within  7 days  of the investigator 
becoming aware of the problem  Investigator  ● Local/internal 
IRBs/Institutional Officials,  
 
All Unanticipated 
Problems  Within  30 days  of the IRB’s receipt of 
the report of the UP from the investigator.  IRB ● OHRP  
 Investigator3 ● External IRBs  
 
8.4. [ADDRESS_914308] tACS would interfere with 
pregnancy.  However, should a participant become pregnant during the study their participation will be 
immediately terminated and will be sent to cons ult with Co -I/ medical monitor.    
8.[ADDRESS_914309] igation  that the seizure was not related to the 
stimulation then the temporary hold of the study will be lifted. If, after investigation into the seizure or Grade III adverse event occurs, and there is found to be further well tested and documented safety measures that can be employed in the study to prevent further seizures or Grade III adverse events, then the temporary hold on the study will be lifted.  If two seizures are witnessed during the study visits, the entire study will be stopped 
prematurely. T hese individuals would be referred for further medical attention. It is very unlikely that a seizure will 
occur, given that previous studies using tDCS in patients with depression and schizophrenia and previous studies in 
the lab using tACS (IRB14 -1622, IRB14 -3285)  have had no seizures occur (Berlin et al., 2013, Brunelin et al., 2012). 
The study will also be stopped if other studies provide evidence that transcranial current stimulation has been 
associated with other, previously unrecognized, potentially harmful effects, either short -term or long -term.  
8.[ADDRESS_914310], a 
biostatistician and one or more clinical researchers. The DSMB will review AEs e very 6 months whereas the 
medical monitor will review AEs in real time and make decisions as to each participant’s continuation in the trial. 
 
[ADDRESS_914311] additional review by [CONTACT_15957] -I on a case -by-case 
basis . The medical monitor will also be present at weekly meetings in order to discuss/explain any event(s) that 
may occur.  
Every [ADDRESS_914312] of participants’ identification numbers from a Frohlich Lab member, not otherwise 
associated with this clinical trial.  Participant identification number will be displayed in a table according to the four  
treatment -sequence groups of the study; howev er the specific treatment regimens of the four groups will not be 
disclosed.  This will allow the DSMB to compare the four  treatment groups.  
Reasons for stoppi[INVESTIGATOR_84005]; decrease in cognitive abilities based on 
baseline and end of study data (>25% decrease in scores in 2/[ADDRESS_914313] participants or 20% of participants 
overall.).   In addition, as mentioned above, if a seizure occurs during a study visit, the clinical trial will be 
temporarily be placed on hold for further investigation.    
9 CL INICAL MONI TORING 
The Purpose of the monitoring plan is to present the Frohlich Lab’s approach to monitoring clinical trials.  The plan 
facilitates compliance with good clinical practice.  
(a) The rights and well -being of human subjects are protected.  
(b) The reported trial data are accurate, complete, and verifiable from source documents.  
(c) The conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and 
with applicable regulatory requirement(s).  
This section identifies key monitoring activities and specifies the data to be reviewed over the course of a clinical 
trial.  This is a single site, investigator initiated, clinical trial so there will be no site monitoring plan in place.  
Frohlich Lab Monitoring Plan 
The latest version of the approved IRB application for this clinical trial will be followed at all times. This 
responsibility falls in the hands of the study coordinator and research assistants.  If at any time there is a deviation from protocol, the deviation from protocol log ( Appendix H) will be filled out.  All team members will be trained on 
how and when to use this log.  The most up to date IRB application will be on file at the Clinical Trials desk in Rm 
233 of the Medical School Wing C. Deviations will be sent to IRB every 4- 6 weeks (if necessary).  
The PI [INVESTIGATOR_676251]. Th e study coordinator or research assistant will keep the PI [INVESTIGATOR_676252]’s continuation in a timely manner, making sure the PI [INVESTIGATOR_676253].  
AE and SAE are clearly defined in the Master Protocol.  Documents of AE and SAE can be found in the study binder 
on file at the Clinical Trials desk in Rm [ADDRESS_914314] with 
reporting of such events ( Attachment 7 ). The PI [INVESTIGATOR_676254] -only access to the redcap data base for this study. 
At any time the PI [INVESTIGATOR_676255] .  This 
 
34 
 allows the PI [INVESTIGATOR_676256], but 
does not allow them to add, change or input any data.  
10 STATISTICAL CONSIDERATIONS  
 
10.1 S TUDY HYPOTHESES  
 
We hypothesize that  
     (1) Daily tACS stimulation for 5 days reduces auditory hallucination symptoms as measured by [CONTACT_226233], PANSS 
and BACS survey instruments, and that  
     (2) weekly tACS stimulation during a follow -up maintenance regimen extends the duration of that clini cal 
benefits as measured by [CONTACT_226233], PANSS and BACS.  
 We hypothes ize that  
     (1) baseline impairment in EEG oscillations  and connectivity  predicts treatment success, and t hat 
     (2) changes in these markers are correlate d with improvement of clinical symptom presentation as measured by 
[CONTACT_226233], PANSS, and BACS.    
 
10.2 S TATISTICAL ANALYSIS PLANS 
The following statistical considerations and aim -specific analysis plans will be reviewed and updated prior to any 
data collection. To help ensure reproducibility and objectivity of the results, these a priori  plans specify detail s for 
the main analyses  for each specific aim; e.g., details of fitted models and decisions regarding the units and scales of 
the measurements of interest .  The plans include  1) sensitivity analyses performed to assess the robustness of the 
major results to reasonable perturbations of the assumptions and methods used;  2 ) exploratory analyses for 
hypothesis generation;  3 ) necessary descriptive graphical an d tabular methods used to visualize the data, and 4 ) 
exploration of relationships among the variables of interest.  Following best practices ( e.g., www.CONSORT -
statement.org), all statistical estimates (e.g., variances, mean s, differences) will be reported  along with their 95% 
confidence intervals  (C.I.s) .  Hypothesis tests that are observed to be not statistically significant will be reported as 
being inconclusive. (Hypothesis tests that are not statistically significant are entirely inconclusive and no conclusions can be drawn from those tests. St atistical test procedure s are incapable of establishing that the null 
hypothesis is true.) The word “inconclusive” will be used when reporting a test that was not statistically significant. To avoid over -reliance on p -values, the focus of the analyses will be on the point -estimates an d interval -estimates 
of the magnitudes of the population parameters of interest (e.g. treatment effects ).  
Plans for Aim 1 :  Evaluate the relative efficacy of the tACS treatment regimen and subsequent maintenance 
regimen in terms of changes in the mean level of the AHRS score.   
Clinical scores ( AHRS, PANS, BACS ) will be recorded on nine occasions (t) :  at baseline immediately before the first 
stimulation session on day 1 (t 0),  after the stimulation session ending day 5 (t 1), and after each weekly 
maintenan ce session  (t 2, t3, t4, t5, t6, t7, t8, t9 ).   The experimental design is best viewed as a 2 -treatment, 
4-sequence (SS, SA, AS, AA), 2 -period randomized crossover with longitudinally repeated measures during the 
second period.  Equivalently, it can also be viewed as a 2 -treatment, 4 -sequence, 9 -period crossover.  
 
35 
 For AHRS,  Y ij(t0)  is the baseline score from the i -th participant in the j -th treatment sequence ( j = SS, SA, AS, AA ).  
The primary analyses will focus a linear mixed -effects model for t he change from baseline on occasion t ,  
∆Yij(t) = Y ij(t) – Y ij(t0),   conditional o n the following explanatory variables:  assigned treatment regimen,  treatment 
stage (initial daily stimulation vs maintenance weekly stimulation), and baseline score Y ij(t0) as a covariate.   
 
[ ∆Yij(t) | X , Yij(t0) ]  =     µ S X1   +   µA X2    +   τS X3   +   τA X4    +   λ X5   +   β (Yij(t0) –Y(t 0))    +     ε i   +   ε ij(t) 
 
Here,Y(t 0) is the average of all baseline values.  The expected value is shown in Table 1  below.  The fitted model 
will be used to tabulate statistical estimates (all with 95% confidence intervals) of the population parameters of interest:  variance components,  intra -class correlation,  the direct effect of treatment ( µ
S - µA) in period 1 ,  
treatment -specific period effects ( τA, τS), and a longer -term treatment effec t (λ) that carries over from period 1 
into period 2.  Parameters τA and τS represent both the period -by-treatment interaction and also the ‘period effect’ 
(τA + τS).  In a 2 -sequence crossover design,  parameters τA, τS and λ would be aliased together ; whereas , in the [ADDRESS_914315] λ  vanishes in the later 
weeks of the maintenance regimen in period 2;  that is,  effects of any treatments in period [ADDRESS_914316] washed out by 
[CONTACT_676282].  (That would not be the case if treatment A in period 1 cured the patient.)  The sensitivity of the main results to this assumption will be investigated in auxiliary sensitivity analysies.   In this 
model, the direct treatment effect in period 1 is ( µ
S - µA)  while the direct treatment effect in period 2 is 
((µ S + τS ) – (µA + τA)).  We conjecture that τ S ≈ [ADDRESS_914317] of treatment that endures into (at least) the beginning of the maintenance regimen.       
 
Table 1.  Co nditional expected value of change from baseline evaluated at the average baseline value  
       Treatment Sequence  
         SS SA AS AA 
Period 1       t1 mS mS mA mA 
Period 2       t2 mS + tS              mA + tA          mS + tS  + l       mA + tA + l 
t3 mS + tS  mA + tA mS + tS  + l mA + tA + l 
t4 mS + tS  mA + tA mS + tS  + l mA + tA + l 
t5 mS + tS  mA + tA mS + tS  + l mA + tA + l 
t6 mS + tS  mA + tA mS + tS   mA + tA  
t7 mS + tS  mA + tA mS + tS   mA + tA  
t8 mS + tS  mA + tA mS + tS   mA + tA  
t9 mS + tS  mA + tA mS + tS   mA + tA  
 For the primary analysis, the above model will be fitted using only AHRS scores at t ∈  { t
1 , t9 }  assuming λ =0: 
E[ ∆Yij(t) | X , Yij(t0) ]  =     µ S X1   +   µ A X2    +   τ S X3   +   τ A X4    +    β  (Yij(t0) –Y(t 0)) 
The set of sensitivity analyses will include fitting the model using AHRS scores at t ∈  { t1 , t6, t7, t8, t9 }  (with λ=0), 
which is anticipated to provide  more precision and power for analysis of the treatment effects.  
 
[ADDRESS_914318]; for 
example,  ( µS − µA )  and ((µS + τS ) – (µA + τA)).    The data and the fitted  model will be visualized via graphical 
figures.  The fitted model using only AHRS scores at t ∈  { t1 , t9 }  will be used to test the primary null hypothesis,  
Ho: “( µS − µA ) = 0  and ( τS – τA) = 0”,  using an F -test of size α = 0.05.    
 
To explore carryover of treatment effects, the model  
E[ ∆Yij(t) | X , Yij(t0) ]  =     µ S X1   +   µ A X2    +   τ S X3   +   τ A X4    +   λ  X5   +   β  (Yij(t0) –Y(t 0)) 
will be fitted using AHRS scores recorded on occasions  t ∈  { t1 , t2, t3, t4, t5, t6, t7, t8, t9 }.   
 Sensitivity analyses will be used to evaluate the robustness of the main results to reasonable perturbations of the methods and assumptions used. This s et of analyses will examine goodness of fit diagnostics for the linear model, 
and will include modified versions of the main analyses.  
Plans for Aim 2 .  Evaluate the relative efficacy of the tACS treatment regimen and subsequent maintenance 
regimen in terms of changes in the mean levels of the PANSS score and the BACS score.  
We anticipate that the strategy and methods used for the analyses of AHRS scores in Aim 1 will also be appropriate 
for the analysis of PANSS and BACS scores for Aim 2.  
 
Plans for A im 3 .  Evaluate the effects of the tACS treatment regimen and subsequent maintenance regimen in 
terms of changes in EEG alpha frequency power levels . 
We anticipate that the strategy and methods used for the analyses for Aim 1 will also be appropriate for the 
analyses in Aim 3 of changes in alpha band power calculated from EEG recordings .  Graphical descriptive statistical 
methods will be used to visuali ze and summarize the temporal trajectories of the scores and alpha band power .  
Scores of clinical assessments  and  EEG recordings at other occasions of the maintenance sessions may be explored 
for the purpose of generating hypotheses.  
Plans for early dis continuation : In the event of a participant discontinuing participation prior to completion of the 
study sessions, the participant’s data set will not be included in analysis. Only completed data sets will be included in analysis.   
 
10.[ADDRESS_914319] that we can successfully recruit 40 subjects from this population.   
 We evaluated the performance characteristics of the study design and analysis strategy under the assumption that 
only 40 subjects will be available.  To do this we  used information from a previous randomized study conducted in 
this lab (IRB 14- 3285) .  That study obtained baseline AHRS scores (Y
0) and post -treatment AHRS scores (Y 1) from 
participants sampled from our target population using the same methods and inclu sion/exclusion criteria .   
Table 2 lists information obtained : 7 patients received sham treatment ( S),  8 received 10Hz tACS  treatment ( A).   
 
37 
  
Table 2.   Parameter Estimates from Previous Study  
 
 
For purposes of our analysis of anticipated precision and power, we conjectured that 1) the variance components have the same magnitudes for treatments S and A,  and 2) the magnitude of intra -class correlation is 0.90.  
The tabulated correlation estimates suggest that the post- treatment AHRS score  is highly correlated with the 
AHRS score at baseline (t
0).  Consequently it is desirable to use the baseline score as a covariate in the linear 
mixed -effects model for AHRS change- from- baseline in order to improv e precision and power for the analysis of 
treatment effects.    Based  on  Table 2  estimates for AHRS,  we anticipate that 20 participants per regimen in period 1 will provide a 
margin of error of about 1.0  AHRS unit  for regimen -specific estimates of mean change from baseline; i.e.,  we 
anticipate a  95% C.I. of the form  [mean change ±  1.0 ]  for each regimen .   
 
For the primary analysis, the model will be fitted using only AHRS scores at t ∈  { t
1 , t9 }:      
E[ ∆Yij(t) | X , Yij(t0) ]  =     µ S X1   +   µ A X2    +   τ S X3   +   τ A X4    +    β  (Yij(t0) –Y(t 0)) 
 We will test H
o: “( µS − µA ) = 0  and ( τS – τA) = 0”,  using an F -test of size α = 0.05.  However,  for purposes of the 
analysis of anticipated power,  we considered a close surrogate:  testing H o: “( µS − µA ) = 0” and Ho: ”(τ S – τA) = 0” 
separately using F- tests each of size α = 0.025.  In Figure [ADDRESS_914320] of  H o: “(µS  − µA) = 0”.   
 

 
38 
 The curves are based on the point -estimates and 95% C.I.  estimates of intra -subject and inter -subject variance 
components expressed here as standard deviations (by [CONTACT_676283])  which are in turn based on the data in 
Table 2 and based on a conjectu red underlying c orrelation of 0.90 between t 0 and t 1.    
 
                
 
The probability (‘power’) of drawing a sample that yields a p -value < α  = 0.[ADDRESS_914321] ( µS −µ A) in the target population. In Figure 2, for example, if our conjectures and 
assumptions are true and in truth ( µS −µ A) = 1.18 AHRS units, the likelihood of rejecting H o:”(µ S -µA)=0” is estimated 
to be 90% with C.I. [50%, 99%].  For  comparison,  Figure [ADDRESS_914322] of H o:”(µ S -µA)=0” based 
on only the data from period [ADDRESS_914323] of  H
o: “( µS − µA ) = 0”  based on AHRS scores recorded on occasions   
t ∈ { t1 , t6, t7, t8, t9 }  assuming carryover effect λ  has vanished before  t 6.  Inclusion of the carryover effect in the 
model can reduce precision and power for the test of treatment effects.    When exploring carryover effects using scores from occasions  t ∈  { t
1 , t2, t6, t7, t8, t9 }  to fit  
E[ ∆Yij(t) | X , Yij(t0) ]  =     µ S X1   +   µ A X2    +   τ S X3   +   τ A X4    +   λ  X5   +   β  (Yij(t0) –Y(t 0)), 
the power curves in Figure [ADDRESS_914324] of  H o: “( µS − µA ) = 0”  when it is assumed 
that carryover impacts the score at t [ADDRESS_914325] procedure s when the sample size is reduced to 30 participants . (Compare to Figures 1, 2, 3 and 4) .  
 Figures 1 - 8   were computed using the ability of SAS PROC MIXED to calculate the non -centrality parameter of the 
distribution of the F -statistic for a competely specified linear mixed -effects model.  The resulting power -curve 
estimates are conjectures based on  1) previous data from only 15 subjects,  2 ) assumptions about the  appropriate 
model for the data,  3) an assu mption that the variance components have the same magnitudes for treatments S 
and A,  and 4) an assumption that the correlation coefficient for the model’s  compound -symmetry covariance 
structure is 0.90.    In summary, based on considerations of anticipat ed precision of estimators,  anticipated power levels of test 
procedures,  anticipated availability of research subjects,  and stage of this line of research,  we anticipate the study is likely  to achieve its specific aims; i.e.,  there is low risk the stud y will be uninformative and inconclusive.  
 The follow- up case study will be used to assess feasibility of long -term maintenance. The sample size is low as we 
do not intend to perform statistical analysis on outcomes. This observational study will be used to inform future, large -scale studies evaluating treatment efficacy of this intervention.  
 

 
40 
                      
 
  
                     
 
 
 

 
41 
 10.4 RANDOMIZATION AND BLINDING  
 
10.4 .1 ENROLLMENT/ RANDOMIZATION/ MASKING PROCEDURES 
Participants will be randomized into one of four  treatment -sequence groups. The randomization assignment will 
occur prior to beginning the initial 5 days of stimulation, once the participant has passed the screening sessions. 
The randomization will be as f ollows: tACS and tACS, tACS and sham, sham and sham, sham and tACS.  This is a 
double blind study, so neither the participant nor the researcher will know which treatment treatment -sequence 
group  the participant has been assigned to.  
A Frohlich Lab member  (Angel Huang ) will randomize 40 codes which will be used by [CONTACT_617779]. These codes will be randomized prior to recruitment of any participants.  These codes are 
directly linked to which treatment regimens the participan ts receive (sham ( S) or 10Hz tACS ( A) ).   
The codes will be randomized using a randomization function available in MATLAB software. A condition will be included so that the same condition will not be assigned to adjacent participants [ADDRESS_914326]. The study coordinator will enter the participant’s study ID next to 
their randomization code on the first day of stimulation.  
(The CONSORT Statement notes that “Allocation concealment is a technique used to prevent selection bias by 
[CONTACT_676284], until the moment of 
assignment.”  Randomization without allocation concealment is not reliable randomization.)    
 
10.[ADDRESS_914327] received stimulation.  
10.4 .3 BREAKING THE STUDY BLIND/ PARTICIPANT  CODE  
This is a double blind clinical trial. The participant and researchers will remain blinded to stimulation conditions 
through the completion of data collection. In the event of an AE/SAE, the PI [INVESTIGATOR_676257].  
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
 
42 
 Human Research Committee (IRB):  
● All IRB Correspondences are on file.  
● The study staff is IRB approved prior to performing any study procedures.  
● Adverse events and deviations are reported to IRB per current guidelines.  
● All versions of the IRB protocols and informed consent forms are on file.  
Informed Consent:  
● Initial consent documented in REDCap via eConsent form.  
● Ensure that participant identification is on all pages of the  physical copy of the  ICF. 
● There is documentation that the participant is given a copy of the consent form . 
● The participant and study representative signed and dated the  consent form for him/herself.  
● The participant initialed and dated all appropriate pages on the informed consent form.  
● Note to file (Appendix G) made for any informed consent deviations.   
● Ensure a valid (current version date) copy of the consent form was used.  
Protocol:  
● Confirm that the study staff is conducting the study in compliance with the protocol approved by [CONTACT_1744]  
● The protocol deviations (exceptions and violations) are documented in the participant chart and reported to 
IRB as required.  
Source Doc uments:  
● Each participant binder will contain a checklist to ensure that each binder has each source document. The checklist will be dated by [CONTACT_456110].  
● Review participant charts to ensure the accuracy, completeness and legibility of the data  
● Any correction made to the source documents is dated, initialed, and explained. The original entry should not be obscured.  
● The protocol specific source documents are on file.  
● Source documents are completed in ink.  
● Note to files (Appendix G ) are made for missing or incomplete data and to explain any discrepancies or 
additional comments.  
Electronic Case Report Forms (eCRF)  
● Ensure the data reported on the eCRF is consistent with the source documents.  
● Discrepancies between the source documents and eCRF are explained in a note to file (Appendix G ) or 
captured in a comment in the eCRF.  
DNA  
● Participant names will not be on any of the samples collected at the initial session. DNA testing is performed 
within the University of North Carolina at Chapel Hill and the samples are not shared with or processed by [CONTACT_226258].  
 
[ADDRESS_914328] access to all of the above information.  Co- I/medical 
monitor will have access to files upon request as t hey will need access to the locked rooms and filing cabinets in 
which these documents are located.  The key linking dummy identifiers with subject information will be securely 
destroyed after completion of data acquisition.  
12 ETHICS/PROTECTION OF HUMAN SU BJECTS  
 
12.[ADDRESS_914329]  
The investigator will ensure that this study is conducted in full conformity with the principles set forth in The 
Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, as drafted by 
[CONTACT_265788] (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal Regulations [ZIP_CODE] (1997).  
12.[ADDRESS_914330] work together to ensure institutional compliance with ethical principles and regulatory requirements. The following is a 
mission statement for the coordinated Human Research Protection Program:  
The University of North Carolina at Chapel Hill is committed to expanding and disseminating knowledge for the 
benefit of the people of North Carolina and the world. An important part of that commitment to knowledge is research of the highest quality on all aspects of the health and behavior of people, and such research is only possible through the participation of humans as research participants. Human participants are partners in research and a precious resource to the university. At UNC -Chapel Hill, human participant research is a privilege, but not a 
right. Consistent with that philosophy, it is the mission of the UNC -Chapel Hill Human Research Protection Program 
to ensure tha t 
1. The rights and welfare of human participants are paramount in the research process;  
2. The highest standards of ethical conduct are employed in all research involving human participants;  
3. Research investigators are properly trained in the ethical and regulat ory aspects of research with human 
participants;  
4. Research investigators deal honestly and fairly with human participants, informing them fully of procedures to be followed, and the risks and benefits of participating in research; and 
Research using human participants at UNC -Chapel Hill conforms to all applicable local, state, and federal laws and 
regulations and the policies of the university.  
12.3 INFORMED CONSENT PROCESS  
 
 
44 
 12.3.1  CONSENT/ ASSENT AND O THER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANT S 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and 
continues throughout the individual’s study participation.  Extensive discussion of risks and possible benefits of tACS will be p rovided to the participants and their families. eConsent documentation  via REDCap is required prior 
to the administration of any assessments used in this study. A physically signed c onsent form describing, in detail, 
the study intervention, device, procedures, and risks will be provided to the participant . Written documentation of 
informed consent is required prior to the administration of any treatment used in this study. All consent forms will 
be IRB -approved and updated with any new information as modifi cation s are made throughout the study.  
12.3.[ADDRESS_914331] participant’s 
willingness to continue will be communicated within [ADDRESS_914332] KEEPI[INVESTIGATOR_1645]  
 
13.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
The study coordinator and research assistants are responsible for the accuracy, completeness, legibility, and 
timeliness of the data reported. Any changes made to the data will involve crossing out the original data, 
documenting the new data with the initi als and date of the researcher making the change.  
The responsibilities designated to each member of the research team are documented on the Delegation of Authority Log (Appendix F ).  The study coordinator and research assistants will be responsible for the informed 
consent process, review for eligibility, questionnaire administration, data entry, device administration, EEG 
administration, and CRF entries. The study coordinator will be responsible for AE/SAE documentation and reporting, while the PI [INVESTIGATOR_676258], review of the AE documentation forms and 
overview of the research staff. [CONTACT_226273] will be the medical monitor for the study.        
13.2 D ATA CAPTURE METHODS   
Clinical data (including AEs, concomitant medications , and expected adverse reactions data) and clinical laboratory 
data will be entered into a data capture system provided by [CONTACT_61604].  The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate.  Clinical data will be entered directly from the source documents.  
Data will be collected in the form of MR scan images. Images will be labeled using a unique study identifier and the 
subject's DOB only. MR images will be stored on a secure PACS server that  is only accessible to the employees 
affiliated with the study.  Those people affiliated with the study, will be able to access the MR images off the PACS 
server. Occasionally, images will be put onto CD or DVD to be passed between research team members. CDsor DVDs will only contain MR images with a DOB and unique study identifier. CDs or DVDs will only be passed between research personnel by [CONTACT_35681].  
 
 
13.[ADDRESS_914333] day of stimulation, the 5th day of stimulation 
and end point (one month follow -up). The BACS will be used to assess cognition in each participant and will be 
used as a safety monitor and data collection tool to monitor any changes throughout the course of the study.  
The stimulation adverse effects questionnaire will be administered after each stimulation in order to monitor any 
side effects the participant may experience from the stimulation treatment. After the last stimulation and at the one week and one month follow -up, participants will be asked whether they believe their symptoms have 
improved due to treatment.  
The AHRS will be our primary outcome for this study. We will administer this questionnaire at the initial session, on the [ADDRESS_914334] maintenance session. 
Eligibility to complete the study will not be determined by [CONTACT_676285].  If the participant is unwilling or 
unable to complete the MRI scan, they will be allowed to continue participation.  
13.4 STUDY RECORDS RETENTION  
According to the University of North Carolina at Chapel Hill’s Archives and Record Management Services sched ule 
for General Records Retention and Disposition Schedule 6.10, records will be kept for 5 years after the completion 
of the study or grant end date, whichever is later.  
13.5 PROTOCOL DEVIATIONS  
All deviations from the protocol will be addressed in study participant source documents. The researcher will 
complete a Protocol Deviation Log (Appendix H ) using the participant code as the identifier. This form will collect 
information such as the date the deviation occurred, details of what the deviation consisted of, any corrective and preventative actions that were taken as a result of the deviation, and the date that the PI [INVESTIGATOR_84010]. The PI [INVESTIGATOR_84011].  A completed copy of the Protocol Deviation Form will be maintained in the regulatory file, as well as in the participant’s source document.  Protocol deviations will be sent to the IRB per their guidelines.  The site PI/study staff will be responsible for knowing and adhering to their 
IRB requirements.  
 
47 
 13.6 PUBLICATION AND DATA SHARING POLICY  
This study will be registered on clinicaltrials.gov once IRB approved. There are no restrictions on publications since 
this is an investigator -initiated study funded by a grant agency (NIMH) that has no influence on the publications 
resulting from this study. The aim is to publish the results of this study in a peer -reviewed, highly -ranked psychiatry 
journal.  
14 STUDY ADMINISTRATION  
 
14.1 STUDY LEADERSHIP  
Principal Investigator: [INVESTIGATOR_124]. Flavio Frohlich, PhD 
Co-I: [CONTACT_226273], MD  
Co-I: [CONTACT_226274], MD  
Study Coordinator : Rachel Force, PhD 
15  LITERATURE REFERENCES  
Ali, M. M., K. K. Sellers, et al. (2013). "Transcranial alternating current stimulation modulates large -scale cortical 
network activity by [CONTACT_187949]." The Journal of neuroscience: the official journal of the Society for 
Neuroscience 33(27): [ZIP_CODE]- [ZIP_CODE].  
 
Antal, A., Chaieb, L., Moliadze, V., Monte -Silva, K., Poreisz, C., Thirugnanasambandam, N., & Paulus, W. (2010). 
Brain -derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans. Brain 
Stimulation , 3(4), 230- 237. doi:10.1016/j.brs.2009.12.003  
 
Arns, M., C. K. Conners, et al. (2013). "A decade of EEG Theta/Beta Ratio Research in ADHD: a meta -analysis." J 
Atten Disord 17(5): 374- 383.  
 
Berlim, M.T., Van den Eynde, F., and Daskalakis, Z.J. (2013). Clinical utility of transcranial direct current stimulation 
(tDCS) for treating major depression: a systematic review and meta -analysis of randomized, double -blind and 
sham -controlled trials. Journal of psychiatric research 47, 1- 7.  
 
Bigdely -Shamlo, N., et al. (2015). "The PREP pi[INVESTIGATOR_19189]: standardized preprocessing for large -scale EEG analysis." 
Front Neuroinform  9: 16. Delorme A & Makeig S (2004) EEGLAB: an open source toolbox for analysis of single -trial 
EEG dynamics, Journal of Neuroscience Methods  
 
Brunelin, J., M. Mondino, et al. (2012). "Examining transcranial direct -current stimulation (tDCS) as a treatment for 
hallucinations in schizophrenia." Am J Psychiatry 169(7): 719- 724.  
 
Brunoni, A. R., J. Amadera, et al. (2011). "A systematic review on reporting and assessment of adverse effects 
associated with transcranial direct current stimulation." The internatio nal journal of neuropsychopharmacology / 
official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 14(8): 1133 -1145.  
 
 
48 
 Brunoni, A. R., M. A. Nitsche, et al. (2012). "Clinical research with transcranial direct current stimulation  (tDCS): 
challenges and future directions." Brain stimulation 5(3): 175- 195.  
 
Cohen, M. X., N. Axmacher, et al. (2009). "Good vibrations: cross -frequency coupling in the human nucleus 
accumbens during reward processing." Journal of cognitive neuroscience 21(5): 875 -889.  
 da Silva, T. L. and A. V. Ravindran (2015). "Contribution of sex hormones to gender differences in schizophrenia: A 
review." Asian J Psychiatr 18: 2- 14. 
 
Delorme, A. and S. Makeig (2004). "EEGLAB: an open source toolbox for analysis of sing le-trial EEG dynamics 
including independent component analysis." Journal of neuroscience methods 134(1): 9 -21. 
 
Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. (2003). The BDNF val66met 
polymorphism affects activit y-dependent secretion of BDNF and human memory and hippocampal function. Cell, 
112(2), pp. 257 –269.  doi:10.1016/S0092 -8674(03)[ZIP_CODE]-[ADDRESS_914335], M. B., & Gibbon, M. (2004). The Structured Clinical Interview for DSM -IV Axis I Disorders (SCID -I) and the 
Struct ured Clinical Interview for DSM -IV Axis II Disorders (SCID -II). In M. J. Hilsenroth, D. L. Segal (Eds.) , 
Comprehensive handbook of psychological assessment, Vol. 2: Personality assessment (pp. 134- 143). Hoboken, NJ, 
US: John Wiley & Sons Inc.  
 Fritsch, B. , J. Reis, et al. (2010). "Direct current stimulation promotes BDNF -dependent synaptic plasticity: potential 
implications for motor learning." Neuron 66(2): 198 -204.  
 
Fröhlich F, McCormick DA.. Endogenous electric fields may guide neocortical network activity. Neuron(2010) 
67:129 –43.10.1016/j.neuron.2010.06.005  
 
Frohlich, F. and S. L. Schmidt (2013). "Rational design of transcranial current stimulation (TCS) through mechanistic 
insights into cortical network dynamics." Frontiers in human neuros cience 7: 804.  
 
Green, M. F., R. S. Kern, et al. (2000). "Neurocognitive deficits and functional outcome in schizophrenia: are we 
measuring the "right stuff"?" Schizophrenia bulletin 26(1): 119- 136.  
 
Gonzalez- Rosa, J. J., Soto- Leon, V., Real, P., Carrasco -Lopez, C., Foffani, G., Strange, B. A., & Oliviero, A. (2015). 
Static Magnetic Field Stimulation over the Visual Cortex Increases Alpha Oscillations and Slows Visual Search in 
Humans. J Neurosci, 35(24), 9182- 9193. doi:10.1523/JNEUROSCI.4232- 14.2015  
 
Harir i, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003). 
Brain -Derived Neurotrophic Factor val⁶⁶ met Polymorphism Affects Human Memory -Related Hippocampal Activity 
and Predicts Memory Performanc e. The Journal Of Neuroscience, 23(17), 6690 -6694.  
 
Jarskog, L. F., R. M. Hamer, et al. (2013). "Metformin for weight loss and metabolic control in overweight 
outpatients with schizophrenia and schizoaffective disorder." The American journal of psychiatry 170(9): 1032 -
1040.  
 
Kanai, R., L. Chaieb, et al. (2008). "Frequency -dependent electrical stimulation of the visual cortex." Curr Biol 
18(23): 1839- 1843.  
 
49 
  
Kay, S. R., Flszbein, A., & Opfer, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. 
Schizophrenia Bulletin, 13(2), 261- 276.  
 
Keefe, R. S., Goldberg, T. E., Harvey, P. D., Gold, J. M., Poe, M. P., & Coughenour, L. (2004). The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a stan dard neurocognitive battery. 
Schizophrenia Research, 68(2 -3), 283- 297. doi:10.1016/j.schres.2003.09.011  
 Keefe, R. E., Poe, M., Walker, T. M., & Harvey, P. D. (2006). The Relationship of the Brief Assessment of Cognition in 
Schizophrenia (BACS) to Function al Capacity and Real -world Functional Outcome. Journal Of Clinical And 
Experimental Neuropsychology, 28(2), 260- 269. doi:10.1080/13803390500360539  
 
Keefe, R. S., C. E. Eesley, et al. (2005). "Defining a cognitive function decrement in schizophrenia." Biolo gical 
psychiatry 57(6): 688- 691 
 Keefe, R. S., R. W. Buchanan, et al. (2013). "Clinical trials of potential cognitive -enhancing drugs in schizophrenia: 
what have we learned so far?" Schizophrenia bulletin 39(2): 417- 435.  
 
Kirkpatrick, B., W. S. Fenton, et al. (2006). "The NIMH -MATRICS consensus statement on negative symptoms." 
Schizophrenia bulletin 32(2): 214- 219.  
 Kleim, J. A., Chan, S., Pringle, E., Schallert, K., Procaccio, V., Jimenez, R., & Cramer, S. C. (2006). BDNF val66met 
polymorphism is associated with modified experience- dependent plasticity in human motor cortex. Nature 
Neuroscience, 9(6), 735- 737. doi:10.1038/nn1699  
 
Kutchko, K. M. and F. Frohlich (2013). "Emergence of metastable state dynamics in interconnected cortical 
networks with propagation delays." PLoS computational biology 9(10): e1003304.  
 
Lawrie, S. M., C. Buechel, et al. (2002). "Reduced frontotemporal functional connectivity in schizophrenia 
associated with auditory hallucinations." Biol Psychiatry 51(12): 1008- 1011.  
 
Miniu ssi, C., D. Brignani, et al. (2012). "Combining transcranial electrical stimulation with electroencephalography: 
a multimodal approach." Clin EEG Neurosci 43(3): 184- 191.  
 
Neuling, T., S. Rach, et al. (2013). "Orchestrating neuronal networks: sustained aft er-effects of transcranial 
alternating current stimulation depend upon brain states." Frontiers in human neuroscience 7: 161.  
 
Nitsche, M. A., W. Jaussi, et al. (2004). "Consolidation of human motor cortical neuroplasticity by D- cycloserine." 
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 29(8): 
1573- 1578.  
 
Nitsche, M. A. and W. Paulus (2000). "Excitability changes induced in the human motor cortex by [CONTACT_676286]." The Journal of physiology 527 Pt 3: 633- 639.  
 
Pezawas L.,Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer -Lindenberg A, 
Weinberger D.R. (2004). “The Brain -Derived Neurotrophic Factor val66met Polymorphism and Variation in Human 
Cortical Morphology.” The Journal of Neuroscience 24 (45): [ZIP_CODE] –102. doi:10.1523/JNEUROSCI.2680- 04.2004.  
 
 
50 
 Polania, R., M. A. Nitsche, et al. (2012). "The importance of timing in segregated theta phase -coupling for cognitive 
performance." Curr Biol 2 2(14): 1314 -1318.  
 
Scherk M (1990), "Fundamentals of dipole source potential analysis". In: "Auditory evoked magnetic fields and 
electric potentials" (eds. F. Grandori, M. Hoke and G.L. Romani). Advances in Audiology, Vol. 6. 
 Seth, A. K. (2010). "A MATLAB  toolbox for Granger causal connectivity analysis." Journal of neuroscience methods 
186(2): 262 -273.  
Shergill, S. S., R. M. Murray, et al. (1998). "Auditory hallucinations: a review of psychological treatments." 
Schizophrenia research 32(3): 137- 150.  
 
Silbersweig, D. A., E. Stern, et al. (1995). "A functional neuroanatomy of hallucinations in schizophrenia." Nature 
378(6553): 176 -179.  
 
Stagg, C. J. and M. A. Nitsche (2011). "Physiological basis of transcranial direct current stimulation." Neuroscientist 
17(1): 37- 53. 
 
Uhlhaas, P. J. and W. Singer (2012). "Neuronal dynamics and neuropsychiatric disorders: toward a translational 
paradigm for dysfunctional large -scale networks." Neuron 75(6): 963 -980.  
 
van der Leeuw, C., Habets, P., Gronenschild, E., Domen, P., Michielse, S., van Kroonenburgh, M., van Os, J., 
Marcelis, M., and for, G.R.O.U.P. (2013). Testing the estrogen hypothesis of schizophrenia: associations between 
cumulative estrogen exposure and c erebral structural measures. Schizophr Res 150, 114- 120 
 
van Rooijen, R., Ploeger, A., & Kret, M. E. (2017). The dot -probe task to measure emotional attention: A suitable 
measure in comparative studies? Psychon Bull Rev. doi:10.3758/s13423- 016- 1224 -1 
 Vicente, R., M. Wibral, et al. (2011). "Transfer entropy --a model -free measure of effective connectivity for the 
neurosciences." Journal of computational neuroscience 30(1): 45 -67. 
 Winterer, G., R. Coppola, et al. (2003). "Functional and effective frontotemporal connectivity and genetic risk for 
schizophrenia." Biological psychiatry 54(11): 1181 -1192.  
 
Zaehle, T., S. Rach, et al. (2010). "Transcranial alternating current stimulation enhances individual alpha activity in 
human EEG." PloS one 5(11): e13766.  
Zaghi, S., M. Acar, et al. (2010). "Noninvasive brain stimulation with low -intensity electrical currents: putative 
mechanisms of action for direct and alternating current stimulation." The Neuroscientist : a review journal br inging 
neurobiology, neurology and psychiatry 16(3): 285 -307.  
  
 
51 
 APPENDIX A: AE REPORT FORM  
Adverse Effects Report:  
Reasons for Report (adverse event, time, date and place of occurrence if available):  
1. What do we already know about the therapy?  
a.  
2. What is th e temporal relationship of the AE to the study therapy?  
a.  
3. Does the AE improve or disappear when the therapy is stopped?  
a.  
4. Is the AE a worsening of baseline symptom(s)?  
a.  
5. Is the AE a result of an underlying concurrent medical condition(s) or concurrent medication(s)?  
a.   
6. Additional Information provided by [CONTACT_84048]  
a.  
Research team member signature ______________________________________ Date____________  
Co-Investigator :  
_____________________________________________________________________________________________
_____________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
Steps to be taken (if applicable)  
_____________________________________________________________________________________________
_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
CI signature _______________________________________________________Date___________  
 
PI [CONTACT_72411]:  _____________________________________________________________________________________________
_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
52 
  
Steps to be taken (if a pplicable)  
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_______________________________________________________________________  
 
PI [INVESTIGATOR_59844] _______________________________________________________Date___________  
 
 
  
 
 
 
 
 
 
 
  
 
 
53 
 APPENDIX B: AE LOG  
 
Participant ID   
√ if AE meets 
definition of 
serious*   
Grade and 
Intensity  
1. Asymptomatic  
2. Mild  
3. Moderate  
4. Severe  
  
Date of 
Incident  
  
Relationship to 
study device  
 
1. Related  
2. Possibly  
3. Not Likely  
4. Not Related  
  
Was Action 
Taken?  
 
 
 
  
Action(s) Taken:  
 
  
Outcome:  
 
1. Recovered  
2. Not Recovered  
3. Recovered w/Sequel  
4. Fatal  
5. Unknown   
PI [CONTACT_74938] / Date  
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
 
54 
 APPENDIX C: SAE REPORT FORM  
Participant ID: _______________ 
1. Location of SAE (e.g., clinic, home): __________________________________________  
2.   Age: ______  
3.  Gender: Male Female  
4. SAE term (provide diagnosis): _____________________________________________________  
4a. If diagnosis is not known, symptoms: ____________________________________________  
5. Date of onset: ________________________ (dd/mm/yyyy)  
6. What is the severity grade of the serious adverse event?  
 
Grade: 1: Mild  Grade 2: Moderate  
Grade 3: Severe  
Grade 4: Life -threatening  
Grade 5: Death  
7. Did the participant receive the investigational product or study intervention prior to this SAE?  
   Yes    No   N/A 
7a. If yes, identify the investigational product or study intervention received prior to the SAE:  
Investigati onal Product/Study Intervention 
Dose_______  
Units_______  
Frequency________  
Start Date _____/_____/______
(dd/mm/yyyy)  
Stop Date _____/_____/______ ( (dd/mm/yyyy)  
Check if On going  
      8. Action taken with investigatio nal product/study intervention:  
Continued Lowered  
 
55 
 Interrupted  
Discontinued  
Increased  
N/A 
9. Outcome of SAE:  
Ongoing at this time  
Resolved without sequelae  
Resolved with sequelae  
Death  
Present at death, not contributing to death  
10. Date of resolution: ________________________ (dd/mm/yyyy) or  
 Ongoing at end of study  
11. Seriousness criteria? (Check all that apply)  
Life-threatening  
Required hospi[INVESTIGATOR_617770]/incapacitating 
Important medical event  
Fatal  
If fatal: 11a. Date of death: ________________________ (dd/mm/yyyy)  
11b. Primary cause of death: _______________________________________________  
11c. Was an autops y performed?  
Yes  
No 
12. Relationship to investigational product/study intervention:  
Related (Associated with the use of the study intervention. There is a reasonable possibility that 
the experience may have been caused by [CONTACT_34144].)  
Unrelated  
 
[ADDRESS_914336]/safety intervention, select all possible etiologies:  
Concurrent illness, disease, or other external factors, specify:  
_____________________________________________________________________________  
Concurrent medication, specify:  
_____________________________________________________________________________  
Secondary study procedure, specify: 
_____________________________________________________________________________  
Accident, trauma , or other external factors, specify: 
_____________________________________________________________________________  
Other, specify: _____________________________________________________________________________  
14. Did the participant receive any relevant concomitant medications in response to the SAE?  
Yes 
 No 
  14a. If yes, please specify: Name, Start and Stop date or On going  
 _____________________________________________________________________________  
15. Did the participant receive any treatments/procedures in response to the SAE?  
Yes  
No  
 
15a. If yes, please specify  
_____________________________________________________________________________  
_____________________________________________________________________________  
16. Did the participant receive relevant laboratory or diagnostic  tests in response to the SAE?  
Yes  
No  
16a. If yes, provide the name [CONTACT_226268]/or supplemental  
  exams below:  
____________________________________________________________________________  
____________________________________________________________________________  
 
57 
 17. Narrative/Comments (provide a description of the serious adverse event including chronological 
clinical presentation and evolution of the serious adverse event and associated signs/symptoms):  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________  
____________________________________________________________________________________ 
____________________________________________________________________________________  
 
18. Completion of form: printed names, signatures and date of signature  
 
[CONTACT_226269] 
(print name)             Person Completing Form                     (signature)  Date  
______________________________________________________________________________  
 
Investigator (print name)  Investigator (signature)  Date  
______________________________________________________________________________  
 
 
 
 
 
58 
 APPENDIX D: UE/SAE LOG  
 
 
Participant ID  
  
  
Date Event 
Occurred   
Date Study 
Team Notified of 
Event  
  
Event  
  
Date Reported to 
IRB 
  
Study SAE Form Completed  
     Yes     No      
N/A      
     Yes     No      
N/A      
     Yes     No      
N/A      
     Yes     No      
N/A      
     Yes     No      
N/A      
 
59 
 APPENDIX E: INFORMED CONSENT QUIZ  
Name [CONTACT_61617]:  
 
 
You have been asked to be in a research  study. This sheet will help you think of questions to ask  but 
you may have other questions.  This is not a test.  We want to be sure you understand what it means 
to be in this research study.  You should understand the research before you decide whether or not 
to participate . 
 
1. What is the purpose of the research ? 
 
 
2. What are the possible benefits  of the research?  
  
3. What are the possible risks  of the research?  
  
4. Will everyone receive the same treatment?  
 
5. How is this research different than the care or treatment I would get if I wasn ’t in the research study?  
 
 
6. Does  in the research cost me anything extra?  
 
7. Can you  stop being in the research once you’ ve started?  
 
 
8.  Who will view your medical  records?  
 
9.   Who do you  call if I have questions about being a research subject?  
 
10.  Any questions?
 
60 
 APPENDIX F : DELEGATION OF AUTHORITY  
Designee (full name)       
Title & Position       
Delegated Activity  
(see codes)       
Designee Signature & 
Dates       
Designee Initials 
(signed)       
 Activity Codes: 
1:  Informed c onsent process        5 :  Creation of randomization codes    9: Stimulation waveform verification  13: Clinical responsibility  
2:  Eligibility verification             6:  tACS  Administration                     10: Safety monitoring  
3:  Questionnai re administration  7:  EEG Administration                      11: AE/UE assessment  
4:  Training of study procedures   8: Data Entry                                      12: AE/UE Doc umentation/Reporting  
 Investigator’s Authorization:  I hereby [CONTACT_226264] -related duties to the following persons and understand that the 
overall responsibility for conduct of the research remains with me.  
1Investigator’s Signature:  [CONTACT_1782]:  
 
61 
 APPENDIX G : NOTE TO FILE  
 
IRB#: 17-1364         PI: [INVESTIGATOR_61580]: ____________________________________________________________________  
Date of Occurrence: ________________  
Research Name: ____________________________________ 
Participant ID: _________________  
Reason for Note: ______________________________________________________________________ 
______________________________________________________________________  
Note: 
_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
_________________________________________________________________________  
Corrective action (if applicable);____________________________________________ 
__________________________________________________________________________________________________________________________________________________________________________________________
________________________  
 
 
 Signature: ______________________________      Date: _______________  
 
62 
 APPENDIX H: PROTOCOL DEVIATION LO G
Participa nt ID  Date 
Occurred  Description  CAPA*  Date PI 
[INVESTIGATOR_676259]/Date  
       
       
       
       
       
       
 
63 
 APPENDIX I: TRAINING LOG  
 
IRB Number: 17 -1364    PI: [INVESTIGATOR_61560], Phd  
 
1      Protocol   3      EEG application  5      Data Entry  
2      Questionnaire Administration   4      Stimulation  6      Other (Specify)  
By [CONTACT_2960], each staff member verifies he/she has  been trained on the information and understand the obligations/responsibilities associated with this training.  
Training Date  Trainee Name  
(please print)  Trainee Signature  [CONTACT_226272]  
(e.g., Presentation,  Self- Study)  Trainer Initials  
 
     
 
     
 
     
 
     
 
     
 
     
     
     
STILL 3 Study  Version 1.0 
Protocol <#>  2 May 2017 
71 
 APPENDIX J: TELEPHONE RECRUITMENT SCRIPT  
Hello, my name [CONTACT_832] __________ and I am contact[CONTACT_676287][INVESTIGATOR_676260]. I am a study coordinator from the University of North Carolina at 
Chapel Hill conducting a research study regarding brain activity in schizophrenia . Your records in the UNC Health 
Care System indicate you may be eligible to participate in our research study OR based on your medical history, 
you may be eligible to participate in our study. 
 
• If participant asks “How did you get my name [CONTACT_3669] [CONTACT_3031] ?”   
o Answer :  We received IRB approval to access medical records of patients in the UNC Health Care 
System who meet our research study criteria.  Based on your medical history, you appear eligible 
to participate in this study.  
• If participate states, “but I am not a UNC Health Care patient, I go to Rex Hospi[INVESTIGATOR_307].”  
o Answer : UNC Health Care System now in cludes several affiliate hospi[INVESTIGATOR_4813], include Rex.  
Do you have time now to hear about the study, answer a few screening questions, and schedule your first visit?  
(If ‘No’, ask for a good time to call back)  
(If ‘Yes’, proceed)  
First, I need to ask for your verbal consent to conduct the screening interview. I will ask questions about your age, 
medication use, psychiatric diagnosis, and  personal health history. You may decline to answer any questions, but 
please keep in mind that this may affect our ability to determine if you qualify for the initial session of the study. Of course, the information you provide is strictly confidential, a nd will not be used for any purpose other than 
eligibility. Do you consent to participate in the screening interview?  
(If ‘No’, thank them for their time and hang up.)  
(If ‘Yes’, proceed.)  
Great! This study is looking at  how  abnormal rhythms of brain activity in schizophrenia respond to very weak 
applied currents.  Findings from this study will help the development of treatments for the symptoms of 
schizophrenia, like auditory hallucinations. In the study, a very weak current will be applied to your scalp. S ome 
people report a mild tingling because of this stimulation, but no other side effects have been found. It is not a shock and should cause no pain.  
Participation in this study includes [ADDRESS_914337] session. The maximum compensation for this study is $760 for completing all of the 
sessions. Are you still interested in participating?  
(If ‘No’, thank them for their time)  
(If ‘Yes’, proceed)  
Great! In order to make sure you’re eligible for the study, I need to ask you a few questions. Please answer yes or 
no. You do not need to provide any further details.  
(If the answer given is not the same as the answer shown , thank the individual for his or her interest and say 
unfortunately, they do not qualify for the current study)  
 
STILL 3 Study  Version 1.0 
Protocol <#>  2 May 2017 
72 
 • Are y ou 18 years old or older?  (Yes)  
• Have you ever, or are you currently being treated for a neurological condition (i.e. epi[INVESTIGATOR_002])? (No)  
• Are you currently taking any benzodiazepi[INVESTIGATOR_1651]? (No)  
o What medications are you currently prescribed?  
 
 
• Do you use any drugs or medications not prescribed, including marijuana, cocaine, etc.? (No)  
o Please note that we will conduct a urine drug test at the initial screening session.  
• Have you ever had brain surgery? (No)  
• Do you have any brain devices or implants, including a cochlear implant or aneurysm clip? (No)  
• Have you ever been diagnosed with a traumatic brain injury? (No)  
• (For females only), Is there a chance you may be pregnant? (No)  
• Have you ever been diagnosed with a mental or psychiatric illness by a professional (i.e. a psychiatrist or other licensed clinician)? (Yes)  
o If yes: What were you diagnosed with?  
• Do you ever experience aud itory hallucinations (i.e. hearing voices or noises no one else can hear)? (Yes)  
o If yes: On average how often does this happen per week?  
 
Follow -up questions:  
• Do you wear glasses/contact [CONTACT_13276]?  
o Could you bring your contact [CONTACT_676288]?  
(If answered according to all indicated responses, continue)  
Excellent! Due to the study schedule, some sessions will be longer than others. Is it possible for you to be available 
from 8 – 5 on weekdays to be at the UNC Hospi[INVESTIGATOR_676261]? If not, can you specify the 
days/times that do not work for you?  
Would you be willing to participate in a 7 hour session for this study? (This includes a 3 hour break).  
You are eligible for participation  in the first session of the study. At the first session we will determine your 
eligibility for the remainder of the sessions.  I’d like to schedule your first session now. It will last approximately 3 
hours. All testing will be conducted at either UNC Hospi[INVESTIGATOR_226232].  (specific location).  
(Schedule a time for first session)  
I will give you a call to confirm your appointment [ADDRESS_914338] any questions before then, please don’t hesitate to contact [CONTACT_676289] r. 
Thank you for your time.  
 